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ABSTRACT 
Parkinson’s disease (PD) current clinical management is mostly based on patient’s subjective report about 
the effects of treatments and on medical examinations that unfortunately represent only a snapshot of a 
highly fluctuating clinical condition. This traditional approach requires time, it is biased by patient’s 
judgment and is often not completely reliable, especially in moderate advanced stages. The main purpose 
of the EU funded project PD_manager (Horizon 2020, Grant Agreement n° 643706) is to build and evaluate 
an innovative, mHealth, patient-centric system for PD remote monitoring.  After a first phase of research 
and development, a set of wearable devices has been selected and tested on 20 patients. The raw data 
recorded have been used to feed algorithms necessary to recognize motor symptoms. In parallel, other 
applications have been developed to test also the main non-motor symptoms. On a second phase, a case-
control randomized multicentric study has been designed and performed to assess the acceptability and 
utility of the PD_manager system at patients’ home, compared to the current gold standard for home 
monitoring, represented by symptoms diaries. 136 couples of patients and caregivers have been recruited, 
and at the end of the trial the system was found to be very well tolerated and easy to use, compared to 
diaries. The developed System is able to recognize motor and non-motor symptoms, helping healthcare 
professionals in taking decisions on therapeutic strategies. Moreover, PD_manager could represent a useful 
tool for patient's self-monitoring and self-care promotion.  
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INTRODUCTION 
Parkinson’s disease 
 
Parkinson’s disease (PD) is a degenerative disease of Central Nervous System that was first described in 1817 by 
James Parkinson (1) and is now recognized as the second most common neurodegenerative disease, second only 
to Alzheimer’s disease. PD is rare before the age of 50 but the prevalence increases with age, affecting 
approximately 1% of the population over 60 years (2) . According to the Global Declaration for Parkinson’s 
disease (3), 6.3 million people are affected by Parkinson's worldwide, with no differences between all races and 
cultures, with slightly more men than women affected. Possibly the disease prevalence will increase in the 
future, because of the general population ageing.  
PD pathophysiology, from a neuropathological point of view, is characterized by the inclusions of Lewy bodies 
and Lewy neurites containing α-synuclein (α-syn) (4). These pathological intra neuronal inclusions lead to 
synaptic dysfunction, interfere with axonal transport and lead to neuronal damage, in particular of 
neuromelanin rich neurons in the dopaminergic substantia nigra pars compacta’s (SNc) caudal and ventrolateral 
regions. The degeneration of the SNc leads to further degeneration of the nigrostriatal system with 
dopaminergic loss in the striatum and causing the core motor features of PD (4). These neuropathological 
features, however, can be early observed also in non-nigral sites such as the olfactory bulb and the enteral 
nervous system. Possibly, during the progression of the disease, the inclusions tend to spread in a cranial 
direction, affecting the cerebral cortex and causing cognitive deficits typical of the late stage (5). The etiology of 
PD is idiopathic in most of cases, in fact less than 3% late onset PD patients have a monogenetic etiology, while 
genetic causes of the disease are more frequent (about 20%) in early onset PD (6). Many genes mutations have 
been associated with PD, both with autosomal dominant inheritance (SNCA, LRRK2, VPS35 and CHCHD2) or 
autosomal recessive inheritance (PARK2, PINK1, DJ-1, ATP13A2, PLA2G6 and FBX07) (6) (7). 
From a clinical point of view, PD is a life-altering but not life-threatening disease. It is predominantly 
characterized by difficulties with body movements, known as “motor symptoms”. The classical description of PD 
symptoms includes an asymmetric presentation of resting tremor, rigidity and bradykinesia.  
Resting tremor is the typical symptom of PD in fact up to 70-80% of PD patients have resting tremor in the early 
disease stages (8). Tremor is frequently observed in the distal parts of the limbs at a frequency of 3-5 Hz. Usually 
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tremor on PD disappears in action as well as in sleep (9) and is exacerbated by emotional stress. Rigidity is 
described as an increase in muscle tone related to a lack of relaxation of the antagonist muscle to a muscle 
actively being contracted in a motion. Extrapyramidal rigidity does not change during the whole range of motion, 
is not dependent on the speed of the movement and is not associated with increased muscle reflexes. In PD, 
extrapyramidal rigidity can be objectified with the presence of cogwheel phenomena during passive mobilization 
of joints. Bradykinesia is another hallmark of PD and is characterized slowness of movement. Bradykinesia can 
cause walking problems with decreased arm swing and postural instability, reduces fine motor skills especially of 
the hands (particularly evident during handwriting) and is also related to hypomimia, another classical feature of 
PD, represented by loss of facial expression. Even when patients are still able to ambulate without assistance, 
limited motor ability due to marked bradykinesia and inability to perform fine and alternate movements lead 
them to dependency in ADLs, being unable to provide for basic personal care like dressing, bathing, and often 
feeding. All these motor symptoms are usually Levodopa (LD) or Dopamino-Agonists (DA) responsive, so in the 
early stage (known as “Levodopa honeymoon period”) the disease is relatively easy to be managed by clinicians. 
However, within 3-5 years, the progressive and complete loss of dopaminergic neurons causes an abnormal 
response to LD with the appearance of motor complications: wearing-off, fluctuations of motor and non motor 
symptoms and dyskinesias. Wearing –off can be defined as the progressive reduction of LD effects before the 
next dose of LD, with re-appearance of tremors, bradykinesia or rigidity. This usually leads to increase the 
frequency of LD daily administrations. Motor fluctuations are changes of motor performances that became 
progressively synchronous with oral LD intake and plasma bioavailability (10) . Motor fluctuations occur in 
approximately 50 percent of patients after 5 years of levodopa therapy (at this time they usually affect patients 
for less than 25 percent of their waking hours), and the proportion of patients affected increases to 70 percent 
among those treated for more than 15 years (11). Dyskinesia is defined as an involuntary abnormal choreiform 
movement of limbs, head or trunk that is induced by LD assumption, especially in long term treated patients. 
Dyskinesia can be observed when blood levels of LD are maximal (peak of dose dyskinesia) or during the onset 
and end of a LD dose (diphasic dyskinesia). In milder forms of motor complications, the symptoms can be 
controlled with modifications of LD doses or with introduction of other drugs such as cathecol-O-methyl 
transferase inhibitors, monoamine oxidase B inhibitors and dopamine agonists including apomorphine. When 
also these strategies are not sufficient, advanced therapies such as LD gastrointestinal infusion, subcutaneous 
7 
 
apomorphine infusion or Deep Brain Stimulation can be adopted (12). Unfortunately, PD patients could also be 
affected by motor symptoms that have poor or no response to dopaminergic treatment. These include axial 
motor involvement causing posture abnormalities, postural instability, gait difficulties, freezing of gait (FOG) and 
falls that can be possibly managed with non-pharmacological interventions such as motor rehabilitation, 
movement strategy training and technology-based interventions (13).  
The incidence of falls in advanced PD is high (40–70%), even if the drug therapy is well balanced. Falls in 
advanced PD are caused by postural instability, dynamic imbalance, orthostatic hypotension, FOG, side effects of 
medications, or postural abnormalities like camptocormia or Pisa Syndrome. Falls lead to injuries and fracture 
that further reduce patient independence and increase the risk of nursing home admission. Patients with 
previous falls often develop fear of falling which further limits their mobility, contributing to increased weakness 
and deterioration (14). 
Another important clinical feature of PD is represented by non-motor symptoms. Non-motor symptoms were 
initially neglected in the classic description of the disease but they have gained attention during the last decade 
(15). For many patients, non-motor symptoms are an important cause of decreased quality of life (16) and 
include psychiatric manifestations such as anxiety and depression, compulsive behavior, dysautonomia (with 
orthostatic hypotension, urinary symptoms and constipation) as well as cognitive impairment, fatigue, REM 
sleep behavior disorder (RBD), excessive daytime sleepiness, restless legs, pain and anosmia. Some non-motor 
symptoms can precede motor symptoms by several years, during the prodromal phase. Especially RBD and 
anosmia have therefore been suggested for screening to identify prodromal or very early PD (17).  
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Figure 1 Clinical symptoms associated with PD progression from Poewe W, Seppi K, Tanner CM, et al. Parkinson disease (18) 
 
Parkinson’s disease monitoring systems 
 
All the symptoms described above show how complex the clinical spectrum of PD can be, especially in the 
moderate-advanced stages, when patients experience an enhanced sensitivity to small changes in plasma L-dopa 
levels, that narrow the therapeutic window and negatively impact motor function (19). The complexity is also 
increased because of the high variability of symptoms between different patients and even within the same 
patient in different moments of the same day. Given the different levels of functional disability, what matters 
most for one patient about disease’s symptoms may not be as important for another (20), so the management 
of motor and non-motor complications should be tailored to the individual subject. This implies a careful 
evaluation to assess for example whether the symptom is a side effect of the medications or is related to the 
progression of the disease. In current clinical practice this is a time-consuming process because fluctuations of 
symptoms are difficult to evaluate accurately (21). There are also symptoms that are rare or episodic (e.g. falls or 
freezing of gait), or behaviors that by definition, take place over long time periods outside the ambulatory room 
(e.g. aerobic and physical activity) and thus difficult to be evaluated by clinicians. Another important point is that 
many patients that live in rural areas or are affected by severe mobility impairments have limited access to 
proper expert care and when delivered, that care is institution based, rather that patient centered. It is mainly to 
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overcome these problems that clinicians and engineers started thinking and developing new management 
solutions. 
Emerging care home-based models are combining remote monitoring, self-monitoring, and multidisciplinary 
care to enable the provision of patient-centered care at home, decreasing the need for in-clinic assessments (22) 
and giving the opportunity to reduce healthcare costs (23). Moreover, these systems are useful to generate real-
time ecologically-valid, accurate, sensitive, and rich datasets not only regarding motor or non motor symptoms, 
but also including contextual information and data such as the time of medication, food intake, sleep quality or 
physical activity, that could be helpful for optimizing multidisciplinary care. The importance of colleting objective 
measurements in PD has been recently analyzed by a panel of experts of Movement Disorders Society (24). This 
is a growing need since currently available clinical evaluation scales suffer from being retrospective, subjective 
and affected by recall bias. Also, PD patients often have difficulty in recognize and correctly report their 
symptoms, for example differentiating dyskinesia from tremor or motor fluctuations from non-motor 
fluctuations. Patients’ diaries of symptoms, even if specifically designed for annotating only PD main symptoms, 
have problems with recall and “diary fatigue” (25), and fail to detect early fluctuations. From a clinical point of 
view, the most useful data coming from home monitoring should be those related to symptoms and features 
that can be measured to reflect therapy effects, including bradykinesia, dyskinesia, fluctuations of symptoms, 
gait parameters and physical inactivity (26), but potentially the applications in diagnosis and treatment are 
various. For example, the discovery of occult disease symptoms, the correct quantification of fluctuations after 
the prescription of a treatment directed at reducing their severity, the precise timing of fluctuation relating to 
meals (e.g. suggesting LD absorption problems), or the more accurate assessment of response to advanced 
therapies, helping in reducing hospitalization after their initiation (24). Personalized strategies are also 
important to support patients’ engagement in their care path, making them active in their own health (27), by 
giving a meaningful and comprehensible feedback about the disease’s status. 
Another important aspect that could benefit from home monitoring systems is caregiver burden, a well known 
problem in PD that is defined as “the extent to which caregivers perceive that caregiving has had an adverse 
effect on their emotional, social, financial, physical and spiritual functioning” (28). The caregiver of PD patient 
has many responsibilities, for example medication administration, care coordination and self-care promotion, 
communication on behalf of the patient, falls prevention, emotional support. Caregiver also plays an important 
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role in directly assisting the person with activities of daily living, especially in the late stages of the disease. 
Identifying and responding to caregiver burden is crucial because informal caregivers make a central personal 
and societal contribution to the support of people with PD. Burden is strongly connected to PD psychiatric 
symptoms, which appear to be highly prevalent (29). A personalized help to caregivers by an adequate and 
objective feedback about the patient’s clinical condition and a detailed education on all PD symptoms and 
complications is a solution that can be provided directly by supporting systems or through clinicians, on the basis 
of data gathered by remote monitoring systems. For example, to reduce the burden of caretakers, a study 
performed by Megalingam and colleagues proposes a wearable health monitoring system that can measure 
heart rate, temperature, electrocardiogram (ECG), tilt, and fall of the homebound patients and can send a 
notification via smartphone to the caregivers if a critical situation is occurring (30). 
 
From a technical point of view, PD monitoring systems are essentially based on wearable devices that can be 
equipped with wide range (31) of different sensors such as inertial sensors, surface EMG, force sensors, portable 
EEG, heart rate sensors. The most studied and used are the inertial sensors. Inertial sensors include 
accelerometers and gyroscopes that can measure respectively the acceleration of a body on the three axis of 
space and its angular acceleration during rotation movements. These sensors are assembled on patented 
devices specifically designed for medical purposes and intended to detect one or more PD symptoms, or can be 
already built-in existing smart-things (such as smartphones, fitness bands, smart watches or tablets). This 
hardware is usually completed by companion software applications (e.g., mobile apps and web-based 
applications) to capture contextual data.  
Wearable devices can be positioned in various body parts, depending on the purpose. Many studies have used 
different combinations of devices placed on wrists, ankles, shoes, hips, lower back. They are secured to patient’s 
body with straps or in some cases integrated in proper clothes (32). Usually inertial sensors on limbs are used to 
detect tremor or dyskinesia, while those placed on foot or lower back are used for gait analysis or FOG 
detection. However, is still not clear which sensor fixed to which body part is best in detecting the various motor 
symptoms and there are no conclusive data on how many sensors are needed (33). In the last 10 years there is 
growing interest on use of these wearable devices in many medical fields, thanks to their objective advantages in 
terms of low power consumption, unobtrusiveness, light weight, reasonable costs and ease of use (34). In the 
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specific area of PD, wearable sensors have demonstrated for example their potential power for diagnosis (35), 
management (36) or to monitor pharmacological trials (37). In fact, specific algorithms and machine learning 
procedures can translate raw data coming from the sensors to quantify main motor symptoms of PD, in terms of 
severity, duration or constancy. For diagnostic purposes, many studies focused on detection of tremor, for 
example in distinguish parkinsonian tremor from essential tremor (38), however, currently reported 
misdiagnosis between resting and essential tremor may occur in 20–30% of the cases (39). Many researches 
focused their work on recognize different types of tremors (resting, action or postural tremor), analyzing the 
various frequency bands properly, and correctly distinguishing tremor from other movements and disorders (e.g. 
dyskinesia or bradikinesia) (40) (41) (42) (43). Several studies used wearable sensors also to detect dyskinesia. 
Tsipouras and colleagues used signals from several accelerometers and gyroscopes, asking patients to perform 
standardised motor tasks or spontaneous movements, to measure levodopa-induced dyskinesia (44). The 
recordings were compared to clinical annotation of the signals and, as a result, they found a sensitivity and 
positive predictive values of approximately 80 %. In another study, the authors used KinetiSense motion sensor 
units (Great Lakes NeuroTechnologies, Cleveland, OH) containing a triaxial gyroscope and triaxial accelerometer 
on three body parts and compared the results with clinical rating of dyskinesia with specific scale (45). The 
authors found that dyskinesia scores predicted by the model using all sensors were highly correlated with 
clinician scores (correlation coefficient of 0.86) and accurate predictions were maintained when two sensors on 
the most affected side of the body were used. Current approaches to detect bradykinesia use various wearable 
inertial sensors (accelerometer with or without gyroscopes) integrated in shoes, watch-like devices or sensors 
placed on different body parts, recording body motions and gait, mainly during specific tasks (for example Timed 
Up and Go test) (46). Various studies showed that several gait parameters recorded by wearable sensor-based 
devices strongly correlate not only with the disease state, but also with bradykinesia scores (47). Gait has been 
extensively studied with non-wearable systems like force plates or optoelectronic gait analysis, that represent 
the gold standard to record many gait parameters (31). However recent studies showed that also wearable 
devices equipped with inertial sensors are able to detect the cardinal characteristics of PD gait. (48) (49) (47). 
Statistical (e.g., mean, variance, skewness, kurtosis), frequency (e.g., energy, power spectral density, 
fundamental frequency), and spatiotemporal/kinematic (e.g., stride length, TUG time, stride velocity) features 
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were extracted and analyzed. Step or stride segmentation were key points for the gait analysis to recognize heel-
strike and toe-off times characterizing the gait cycle and the complete walk (31).  
However, the use of wearable devices is not free from limitations. For some authors (50), data collected in home 
environment still not able to provide sufficient information about motor symptoms and, for instance, is still 
difficult to infer if detected slowness of movement is real bradikinesia or just fatigue, fear of falling or simply 
slower gait speed due to contextual factors. Moreover, the monitoring systems are mainly focused on motor 
symptoms, while patients often report large part of disability be originate from non-motor symptoms. 
Unfortunately, only few studies were focused on the complex and highly variable clinical manifestations (51) 
(52). Another aspect is that only few systems most wearable systems are not compatible with each other, so it 
might be difficult or even impossible to combine data gathered developed from different manufacturers, with 
deducible limitations in terms of applicability and usefulness of the data. Finally, especially for home monitoring 
system are crucial the usability and the wearability of the devices, to avoid a low rate of engagement among 
patients: as shown by a recent study demonstrating that 32% of users stop using wearables after 6 months, and 
50% after just over a year (53). Lack of motivation to use wearables/self-monitoring systems should not be 
underestimated, particularly in the absence of meaningful feedback provided to their users. Preliminary 
evidence suggests that patient empowerment and their inclusion as active players in the development of 
research activities may favorably impact compliance (54), and the future development of monitoring systems 
should consider this aspect. In Table 1 un-meets needs in PD monitoring technologies are summarized, together 
with already achieved goals and future perspectives of development. 
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Table 1 Examples of available and needed technologies relevant to the diagnosis and clinical management of patients with Parkinson 
disease (50) DBS: deep brain stimulation; EMG: electromyography; GPi: globus pallidus pars interna; PD: Parkinson disease; REM: rapid eye 
movement; STN: subthalamic nucleus; Vim: Ventrointermedial nucleus 
 
PD_manager Project 
 
The PD_manager Project is a European Project, founded by The EU Framework Program for Research and 
Innovation (Horizon 2020, Grant Agreement number 643706), that has the aim to build and evaluate an 
innovative, m-health, patient-centric system for Parkinson’s disease management. Ten different partners from 
all over Europe are involved in the Project, including Universities, Research Hospitals and Private Companies, 
each one with different tasks and goals, but working all together to develop a new solution for home monitoring 
and care. The System is designed to use unobtrusive wearable devices for motor symptoms detection and 
quantification, but also a series of applications to monitor also non motor symptoms. The selection of features, 
tools and output of PD_manager is based on a user needs analysis (patients, caregivers, neurologists and other 
health-care providers). It examines current practices around every-day and specialist management of 
Parkinson’s disease, and identify where these practices may be enhanced or complemented by technological 
and/or process support. On the basis of a needs analysis, a detailed specification of the tasks entailed in 
supporting and managing the disease will inform design specifications of technological support tools as well as 
providing educators and policy-makers with a clear and comprehensive view of the current and future nature of 
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Parkinson’s disease management. From this task analysis, the information requirements necessary to support 
each task faced by each kind of user can be specified, which serves as a detailed specification for designing the 
PD_manager user-system interface.  
A set of unobtrusive, simple-in-use, co-operative, mobile devices has been selected for symptoms monitoring 
and collection of adherence data. The set will consist of an Android Smartphone (with accelerometer and 
dedicated apps installed), a wristband (with sensors for heart rate and accelerometer and gyroscopes), and a 
pair of sensor insoles (with capacitive pressure sensors as well as a 3D acceleration sensor for the measurement 
of motion sequences). This combination of devices will be tested to verify the system’s capability to correctly 
assess motor symptoms (initially with data from 20 inpatients with motor complications, then in home 
monitoring regimen). Patients are commonly assessed in physician office with the Movement Disorders Society 
UPDRS (55) to evaluate general severity of motor disability. Nonetheless obtaining long-term, objective 
information on motor status using an unobtrusive approach, that minimizes visits to the clinicians’ office, is very 
important for the assessment of disease progression from the treating clinician with emphasis in the 
management of the wearing-off. Specifically, the patient, with the possible support of his caregiver, will be able 
to monitor occurrence of motor symptoms such as tremor, dyskinesia, bradykinesia, gait, posture, balance, with 
the sensor insole, as well as the accelerometers of the wristband and of the smartphone will provide the 
necessary raw data needed for that purpose. Also, detailed studies of the analytical strategies and knowledge 
sets used by expert health-care providers (e.g., neurologists undertaking diagnosis activities) will inform the 
design of a decision-support system (DSS) embedded within PD_manager. The DSS is potentially a very useful 
instrument for clinicians, because it will be able to suggest if and how modify drug therapy, based on symptoms 
detection and analysis. Medication, nutrition and physical activity and physiotherapy plans will be proposed by 
the system and will be approved and adjusted by the neurologist, the nutritionist or the physiotherapist 
respectively and will be available for the patient and the caregiver through a mobile app. The definition of 
factors and signs just before wearing off, that could constitute a sort of premonitory index of ON/OFFstatus, will 
also be studied during the data mining studies. The System will also propose and validate strategies to help 
physicians and healthcare professionals to search and evaluate the most diagnostic information (i.e., the 
information that is most relevant to help PD patients to cope with their symptoms, relief from them and make 
the best of their resources). Usually consultations are very short, so the feedback needs to be short and 
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integrated into the daily working routine of the health professional. Moreover, medical staff and patients usually 
decide the treatment plan and its modifications together – shared decision making. This decision-making is on 
the basis of subjective experiences by the patient / carer (self-report), and on the basis of objective assessment 
(available thanks to PD_manager) of motor, cognitive, and non-cognitive symptoms, as well as the level of 
adherence to the suggested management plan. Furthermore, objective data ought to be combined with 
subjective symptoms (e.g., depression, impulse control disorders, and cognitive dysfunction) referred by the 
patients to gain a holistic view on the patient’s state. This holds true especially at the stage in which PD patients’ 
response to medications becomes unpredictable and clinicians have to make decisions about whether and what 
changes in the disease management should be made. This will allow to better understand experts’ use of the 
available information that will in turn inform and guide the development of models and the setup and the 
revision of the mobile devices. In this way, there will be a feedback loop between the design of technologies and 
the knowledge acquired about the procedures routinely adopted by clinicians. At the same time, the policy and 
ethical framework under which Parkinson’s disease is managed will be assessed. These outcomes of behavioural 
modelling will be validated within a computational modelling framework, which will establish the viability of, and 
constraints on, the PD_manager support environment. 
Regarding non-motor symptoms monitoring, PD_manager will focus on the emotional state of the patient, his 
cognitive problems, his speech disturbances and any sleep disorders he may be experiencing. All this information 
will reinforce the collected dataset about the patient and enable clinicians adopt a more complete approach for 
the management of the disease. Caregivers will greatly contribute to the collection of correct information for 
non-motor symptoms. Specifically, the project will support the evaluation of the overall non-motor symptom 
frequency and severity, impulsiveness, depression and compulsive behaviour with neuropsicological scales and 
using a brand-new smartphone application with dedicated games and tests. An objective evaluation of speech 
disturbances will be also implemented: vocal impairment relevant to PD is described as hypophonia (inability to 
produce normal voice pitch) and dysarthria (difficulty in articulating words). The research effort will be to classify 
patients and the progress of the disease based on their speech problems. 
Specific Project partners will conduct a dedicated nutritional study for Parkinson's. The resulting mobile 
application will support each patient to set nutritional priorities based on the issues they face. The nutritional 
issues faced by patients with PD are complex and diverse. For example, PD patient needs to eat regularly, eat a 
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variety of foods from all of the food groups and eat prudently to maintain a healthy weight. Although this sounds 
like simple advice, its implementation can be a challenge, particularly when the symptoms of Parkinson's are 
affecting the patient’s ability to shop, prepare food, and eat. Moreover, constipation is common in Parkinson's 
disease. Although the constipation observed in Parkinson's is due in large part to the disease itself, lifestyle 
measures can be useful for managing it. Finally, the medications used for Parkinson's can themselves cause 
nutrition-related side-effects, such as nausea and poor appetite, which can lead to undesired weight loss. 
Typically, these side-effects are most severe when a medication is first prescribed but some individuals have 
continuing problems with them. Amino acids (from dietary protein) can interfere with the uptake of levodopa 
into the brain. The PD_manager mobile app designed for nutrition support will be linked to the Open Platform 
for Clinical Nutrition (OPEN) (56), which is a freely accessible web-based application (developed by one of the 
Project partners) that supports food and physical activity recording and diet planning. It enables online 
interaction between a dietician and his patient. To support its use in different countries and languages, OPEN 
allows translation of the user interface into any language as well as the use of any food composition dataset that 
complies with Food data structure and format standard (BS EN 16104:2012). By default, OPEN refers to 
international dietary recommendations, which can be modified by the dietician to suit the needs of individuals. 
With PD_manager nutrition app, the patient will be able to build a personalized nutritional strategy. In early 
Parkinson's, the PD_manager will serve as online consultant educating patients and their caregivers. When the 
disease progresses, and new symptoms emerge (such as swallowing difficulties, medication side-effects, bowel 
issues, and eating challenges), the PD_manager will recommend dietary changes to manage and reduce such 
symptoms. As the goal of thoughtful nutrition is not just to ease PD symptoms, but also to allow the patient to 
continue to use food as a source of pleasure in his life, the PD_manager will motivate patients to enjoy in 
cooking and eating.  
Another task of the Project is dedicated to empowering of game-based physiotherapy at home. Various serious 
games will be developed for that purpose, on different platforms: one tablet and two different optoelectronic 
infrared sensors. These games will provide specific scenarios that will encourage and motivate the patient on 
making selected exercises as prescribed by physiotherapists. Each game will collect data on patient’s movements 
and progression that will then be available to doctors and physiotherapists for overview and tracking of patient’s 
progress. 
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Finally, one last important part of the project is the educational module for patients, caregivers and healthcare 
providers. The focus will be on occupational and speech therapies in order to provide access to these services 
particularly for people with limited financial capabilities, since in most countries such services are provided only 
by private sector. An educational video gallery will be built for that purpose. 
An open architecture based on Fi-ware Generic enablers will support the use of any commercial set of sensors 
within the Internet of Things concept. A robust knowledge management platform (KMP) will be designed and 
developed that can be used for different purposes from health professionals and public health monitoring 
authorities. In PD_manager, the KMP will be used for informing a DSS that will suggest disease management 
modifications to the clinician, who can then approve these modifications and send them to patients and 
caregivers. 
Other Projects have been developed to test similar approaches to PD monitoring. For example, SENSE-PARK (57) 
seem similar to PD_manager in terms of measurements and patient monitoring, but to a closer look they are 
very different: PD_manager proposes a holistic mobile approach that includes education and gives emphasis in 
adherence to the medical recommendations. Moreover, the open, based on the Internet of Things concept, 
knowledge management platform that will be developed as well as the studies of experts’ behaviour and 
patients nutrition and physiotherapy and the effort to build a DSS that suggests modifications in the medication 
plan take the PD management a step beyond the concept developed in SENSE-PARK. Actually, the SENSE-PARK 
sensor system could be a way to test the open nature of the PD_manager knowledge management platform and 
the features extracted from this sensor system could feed the PD_manager DSS instead of the data captured 
with the mobile devices proposed in PD_manager. Providing disease state-defining parameters and constantly 
giving feedback to patients, that are main objectives of the SENSE-PARK project, will be core features of the 
PD_manager system too and thus clustering will be needed in order to better address these two issues. Another 
Project on PD monitoring is REMPARK (58) - Personal Health Device for the Remote and Autonomous 
Management of Parkinson’s Disease, that focuses only in the motor status of the patients without a more 
holistic approach. There are no duplicated efforts in gait analysis since the sensor insoles approach adopted in 
PD_manager is innovative and studied for the first time. Moreover, postural gait analysis is just a sub-task in 
PD_manager since the objective is to have data that will be evaluated by the clinician and the DSS, while 
REMPARK is developing an autonomous gait guidance system as a core activity. In CUPID (59) Project the goal 
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was to implement a closed-loop system for personalized and at-home rehabilitation of people with Parkinson's 
disease, using sensors, audio biofeedback, exergaming and external cueing to provide intensive motivating 
training, monitored remotely by experts, for at home rehabilitation. The scope of PD_manager is to suggest 
medication modifications based on the evolution of symptoms, and the patient’s adherence to the prescribed 
management plan that of course includes rehabilitation in most patients. Adherence to physiotherapy through 
video games will be just an aspect of PD_manager since it is necessary in order to provide a holistic approach for 
the management of the disease, but the study will not go as deep as CUPID does in this field. Thus the 2 projects 
actually complement each other. The feedback from CUPID could be integrated as input for the PD_manager 
DSS and thus clustering should be sought. 
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OBJECTIVES 
 
The PhD candidate has developed his research and study in the context of PD_manager Project, working as 
medical doctor in Research Hospital San Camillo IRCCS (Alberoni, Venice Lido), clinical partner of the Project’s 
Consortium. During the PhD course, the candidate has also worked together with other clinical and technical 
partners in a tight interplay to complete the tasks requested. 
The main objectives were: 
- The design and completion of a Pilot Study on 20 inpatients wearing a set of wearable devices. The Pilot 
Study aims to collect a well-organized set of raw motor data, that will be analyzed to test if the System, 
using the measurements coming from the devices, is able to recognize the main motor symptoms of the 
disease. 
- The design and completion of a Multicenter Study to assess the acceptability and usability of the 
PD_manager System at patients’ home, compared to currently used practices for home monitoring and, 
from clinician point of view, to test the utility in terms of providing useful information for medical 
decisions and practicality of the mHealth platform.  
The secondary objectives were: 
- The creation of an educational video gallery for patients and caregivers 
- To contribute in the creation of an automated Decision Support System for clinical management 
optimization 
- To contribute in the development of a Cognitive App for monitoring of cognitive status 
- To collect clinical data and vocal recordings for Voice Recognition App implementation 
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MATERIALS AND METHODS 
 
Pilot study 
 
The Pilot Study is a key pillar of the PD_manager project since it provides the basis for the second phase of the 
project, the Multicentric study. The main purpose of the Pilot Study is to verify if the selected wearable devices 
are able to detect and quantify the main PD motor symptoms. To do that, a well defined set of raw motor data 
have been gathered and analyzed by signal processing and data mining procedures for detection and evaluation 
of motor symptoms and fluctuation of symptoms. Other important goal of the pilot study was the analysis of 
selected non motor symptoms: cognitive status and speech. The data gathering of these two aspects has been 
integrated with the recordings of motor symptoms in a comprehensive protocol, together with clinical and 
demographic data, user needs analysis and usability and wearability evaluations. The pilot study has been 
specifically designed to obtain data from all these aspects, both in on and in Off condition with a precise 
schedule.  
Patients 
 
A total number of 20 patients was required for this pilot study. The involved Clinical partners of the Project 
contributed as follow: 10 hospitalized patients have been recruited at IRCCS Fondazione Ospedale San Camillo 
(Venice, Italy), 5 outpatients at IRCCS Santa Lucia (Rome, Italy), 5 outpatients at University Hospital of Ioannina 
(Ioannina, Greece). 
The inclusion criteria are specific requirements that have to be satisfied to enroll a patient. For this study, the 
selected requirements were a diagnosis of idiopathic Parkinson’s Disease (according to the UK Brain Bank 
criteria) and a Hohen &Yahr (60) score between 3 and 4 (during the OFF state). This second criteria was chosen 
to select a cohort of patients representative for a moderate-advanced disease stage. In fact, in this stage the 
symptoms are less responsive to drug therapy and patients start to present motor complications or initial 
cognitive impairment, so this kind of patients are the optimal target population for home monitoring systems 
usage and evaluation. The exclusion criteria were: co-morbidities with stroke or other brain disease, severe 
cognitive impairment (or dementia) and inability to walk.  
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For each patient have been collected essential clinical information such as: age, initial diagnosis. side of onset 
(side of the body where the motor symptoms began), disease duration, current symptoms, current treatment 
(duration, current dosage: Levodopa Equivalent Daily Dosage, Dopamine Agonist Equivalent Daily Dosage), 
previous treatment (duration), years under levodopa, presence or history of psychiatric disease, psychiatric 
treatment, comorbidities, other medications (from comorbidities). Before each recording session, specific MDS-
UPDRS subitems have been scored, in On and Off state (see below, Pag. 25 Motor recording protocol and MDS-
UPDRS Subitems evaluation). 
Devices and Applications 
Moticon's sensor insoles 
Sensor insoles, produced by Moticon, is an every-day, flexible and thin solution (Fig. 2a) to measure distribution 
of pressure, acceleration, weight-bearing, balance and motion sequences. This is achieved with 13 capacitive 
pressure sensors as well as a 3D acceleration sensor and a temperature sensor which are integrated in the insole 
for the collection of data. OpenGo science (61) (that is the technology used to program the sensor insoles) is a 
system for the measurement of plantar pressure distribution that is universally applicable and open for 
application developers. It is ideal for the use in clinical research and particularly in the fields of rehabilitation and 
training analysis. The patients will wear these insoles inside their shoes, during the recordings. 
Beaker Software 
The Beaker software, developed by Moticon, was necessary for the implementation of the recordings using the 
insoles, and was also used for the synchronization of data. Inherently Beaker allows importing other 
synchronized raw data (e.g. signals from wristband and smartphone). The user can decide which data can be 
visualized (Fig. 2c). Beaker also supports video importing and automatic synchronization through filming QR 
codes at the beginning of the recording. In this way the researcher can visualize at a single screen the detailed 
gait analysis, as many other available signals, the video of the patient for a visual analysis of the symptoms and 
their correlation with the signals from the patient. All data are synchronized and ready for further analysis (Fig. 
3). 
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Figure 2 a) the wearable devices; b) clinical setting; c) Beaker Software 
 
Figure 3 Data from all devices are merged in Beaker software and analysed together 
Smartphone and PD_manager App 
For the needs of the data gathering of Pilot Study, a monitoring and data collection mobile app was designed 
and developed. The App, based on Android operating system, is installed on a smartphone (Aquaris M5, BQ™, 
Spain) that will be located into patient’s pocket during the motor recording protocol. The smartphone’s brand 
a) 
c) 
b) 
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has been chosen by technical partners. The PD_manager App allows to gather raw data from the sensors of the 
Microsoft® Band to the paired smartphone, as well as raw data from the sensors of the smartphone itself. In this 
section the basic functionality (Fig. 4) of the mobile and its use in the context of data gathering is provided; a 
detailed analysis of the implementation will be presented in the Results section. Another BQ smartphone, with 
the PD_manager App installed, is used by the clinician to annotate the presence of motor symptoms during the 
recording sessions (Fig. 4 d) 
  
Figure 4 PD_manager App for Android Smartphone a) start/stop recordings; b) Signals monitoring; c) Sensors selection; d) clinicians 
annotations app 
Wirstband and Microsoft® Health App 
The Microsoft® Band 1 is a wearable device, a wristband, that can be used to track the user’s activities, using 
several sensors (62) Measurements of the fluctuations in heart rate make Band’s measurements of calories 
burned and exercise and sleep statistics more precise. In PD_manager we use the raw data coming from the 
wristband for correlations with other signals. A 3D accelerometer, along with the gyroscope the motion data are 
used to calculate statistics like number of steps taken, which can be combined with info from the profile and 
heart rate measurements. GPS that records routes and collects info about the distance. And the GSR (Galvanic 
Skin Response) that measure skin conductivity. The GPS data could be used to refine distance and speed 
calculations, but not in this project. For the purpose of this task we have collected raw data only from the 3-axis 
accelerometer, the gyroscope, steps and heart rate. Future versions can be extended to include more signals and 
raw data, e.g. from GPS or GSR. To correctly pair Microsoft® Band to PD_manager App, on the smartphone we 
have also installed Microsoft® Health app (63) that provides actionable insights based on the rich data gathered 
a) b) c) d) 
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from the band and any other fitness devices and apps the patient may use every day. Microsoft® Health makes 
tracking personal activity easier, more insightful, and more holistic. In this study, analysis of data performed by 
from Microsoft® Health will not be used, but in the future, this app can be integrated in the mHealth platform to 
monitor physical activities and also sleep quality. 
Cognitive Test App 
While the automatic detection and assessment of the motor symptoms is a topic that has been largely studied 
and is in the focus since mhealth is considered for PD, the evaluation of the cognitive status in PD patients and 
the integrated study of cognitive and motor progression is not so well addressed. With this purpose, in the 
context of PD-manager Project, a mobile application (Cognitive Test app) was designed and developed in 
collaboration with technical partners of Universidad Politecnica de Madrid, in order to track the 
neuropsychological trend of the patient, along with motor fluctuations. Before the Cognitive Test administration, 
the patient has to perform the Finger tapping task: the patient is asked to touch, with one finger at first and then 
with two, one or two buttons on the smartphone screen as fast as possible within 10 seconds. This simple motor 
task is aimed to set the Cognitive Test software, based on the reaction time of each patient, to calculate the time 
needed to perform each test. This mobile application has been used during the Pilot Study with two main 
objectives: 1) to explore the feasibility of a mobile application for this kind of assessment in PD patients, 2) to get 
actual feedback from the patient in terms of usability and user experience, in order to modify the app design and 
tests if needed. Several Cognitive tasks have been evaluated and, based on clinicians’ indications, a Cognitive 
Test App has been developed. The following tests have been selected: 
a) Paired Associates Learning: In the first part of the test boxes are displayed on the screen and opened in a 
randomized order. One or more of them will contain a pattern. In the second part of the test, the patterns are 
displayed in the middle of the screen, one at a time, and the participant must touch the box where the pattern 
was originally located. The difficulty level increases through the test. The number of patterns to locate will 
increase along with the difficulty level (from one in the first level to eight in the last level). If the participant 
reaches the 6th level, the number of boxes will increase from 6 to 8. If the participant locates correctly the 
pattern, a positive feedback will be showed (a green tick mark and a positive auditory signal), otherwise a 
negative feedback will be showed (a red x mark and a negative auditory signal). To skip to the next level, the 
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patient must locate correctly all patterns. In case of error, the level is repeated, and the pat-terns are 
represented to remind the participant of their locations. If participant locates wrongly all patterns in two con-
sequent trials of the same level, the test will stop.  
b) Pattern Recognition Memory: The participant is presented with a series visual patterns, one at a time, in the 
center of the screen. These patterns are designed so that they cannot easily be given verbal labels. After the 
presentation phase, there is a recognition, in which the participant is required to choose between a pattern he 
has already seen and a novel pattern. In each level, the test patterns can be presented in the reverse order to 
the original order of presentation (reverse mode) or in a totally random order (random mode). If the participant 
selects the correct pattern, a positive feedback will be showed (a green tick mark and a positive auditory signal), 
otherwise a negative feedback will be showed (a red x mark and a negative auditory signal). The difficulty level 
increases through the test, i.e., the number of patterns increases from two –first level - to six – last level -.  
c) Spatial Working Memory: The test begins with eight white squares boxes being shown on the screen. The aim 
of this test is that, by touching the boxes and using a process of elimination, the participant should find one blue 
‘token’ only in a few of the white boxes presented on the screen and use them to fill up an empty column on the 
right hand side of the screen. The number of blue ‘tokens’ is gradually increased, up to eight boxes.  
d) Spatial Span: Eight white squares are shown, some of which briefly change color in a variable sequence. The 
participant must then touch the squares which changed color in the same order that they were displayed by the 
device. In each level, there are three trials with the same spatial configuration of white squares and the same 
length of variable sequence. The sequence of colored boxes will get as long as the level difficulty increases (from 
two colored boxes in the first level to eight colored boxes in the last level). To skip to the next level, the patient 
must make correctly at least two of three trials. However, with two or more incorrect trials the test stops.  
e) Stop Signal Stop: This test consists of two parts. In the first part, the participant is introduced to the press pad, 
and told to press the left hand button when he sees a left-pointing arrow, and the right hand button when he 
sees a right-pointing arrow. In the second part, the participant is told to continuously press the but-tons on the 
press pad when he sees the arrow, as before, but, if the arrow presentation is combined with an auditory signal 
(a beep), he should withhold his response and not press the button.  
The number of trials of each part is 50 and the length of each trial is three seconds.  
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f) Attention Switching Task: The test displays an arrow which can appear on either side of the screen (right or 
left) and can point in either direction (to the right or to the left). Each trial displays a cue at the top of the screen 
that indicates to the participant whether he has to press the right or left button, according to the “direction in 
which the arrow was pointing” (first part) or the “side on which the arrow appeared” (second part). Some trials 
display congruent stimuli (e.g. arrow on the right side of the screen pointing to the right) whereas other trials 
display incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side of the screen 
pointing to the left). The total number of trials of each part is 13.  
g) Visual Analogue Scales: The participant must respond to 8 questions, as they appear on the screen by 
touching the on-screen slider and moving it to the appropriate position on the scale 
Speech Recognition 
Some people with PD experience changes in cognition and language, i.e. difficulty to think quickly, to manage 
multiple tasks, to find words or to understand complex sentences. These changes, even if subtle, can make it 
challenging for a person with Parkinson’s to follow a conversation. In some cases, the patient cannot retrieve the 
word that he/she is thinking about; this condition is called anomia. At the same time, a typical feature of PD 
patients’ language may consist in a ‘flatter’ voice (lack of prosody), associated with poor facial expressions. 
About 90 per cent of people with PD will experience changes in their voices or their ability to make speech 
sounds at some stage of their lives. Most commonly, the voice becomes quieter (hypophonia)(10). It can also 
develop a breathy or hoarse quality. These changes may result in less precise speech, which is more difficult to 
understand, especially when speaking to persons who have hearing loss. The speed of talking changes also due 
to PD. Some individuals with PD may speak more slowly, others accelerate their speech so much that they 
stumble over sounds and seem to be stuttering (tachyphemia). To perform the speech recordings the 
Smartphone have been used, with installed a Smart Voice Recorder app (64). 
Recordings 
Motor recording protocol and MDS-UPDRS Subitems evaluation 
The motor recording protocol is a set of simple motor tasks that the patient performed during the recording 
sessions and which simulate daily activities such as sitting in a chair, opening a door, etc. Every task aims to 
trigger specific symptoms of the disease. The motor recording protocol is needed to standardize a reproducible 
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recording setting and to collect consistent data across the 3 clinical sites involved. As resumed in Table 2, for 
each enrolled patient the protocol has been repeated 8 times in 4 different days, in fact for each “recording 
day”, two recording sessions have been planned: one in ON and one in OFF state.  
 
Table 2 Recordings schedule 
In general, the patients have been asked when they usually are in OFF state and the first session of the day is 
performed at that time. If, thanks to medical treatment, the patient did not present a clear OFF state, in order to 
make sure to record a real “OFF state”, the session have been planned in the morning, avoiding to administrate 
the first daily dose. The dose has been administered immediately after the recording session. To record an “ON 
state” it has been sufficient to plan the session from 30 minutes to 1 hour after any of the L-Dopa or Dopamine-
agonists doses that the patient usually takes during the day.  
Before each recording session, the clinician evaluates the patients scoring the MDS-UPDRS subitems showed in 
Table 3. 
Symptom MDS-UPDRS Subitem number Range 
Speech 3.1 0-4 
Rigidity Severity on Right Arm 3.3b 0-4 
Rigidity Severity on Left Arm 3.3c 0-4 
Finger tapping Right Hand 3.4a 0-4 
Finger tapping Left Hand 3.4b 0-4 
Gait 3.10 0-4 
Tremor Severity on Right Arm 3.17a 0-4 
Tremor Severity on Left Arm 3.17b 0-4 
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Tremor Severity on Right Leg 3.17c 0-4 
Tremor Severity on Left Leg 3.17d 0-4 
Was dyskinesia present? / yes/no 
Table 3 Selected Updrs Subitems with respective number and score range 
When the patient is ready he/she has been asked to wear the insoles inside his/her shoes, the wristband on the 
wrist of the more affected side, and the smartphone inside trousers’ pocket; the clinician keeps the other 
smartphone in order to annotate any motor symptoms that occurs during the recording session. 
The core activity of the whole Motor Recording Protocol is the recording of motor tasks. During the recordings of 
motor tasks, 3 people are involved: the patient that must complete the tasks wearing the sensors (Smartphone, 
Wristband and Sensor insoles); the clinician that guide the patient and also annotates the symptoms; an 
operator that performs the video recordings. The annotation of symptoms, performed by the clinician, is made 
using a second smartphone as described. When all recordings are started, the patient is asked to complete a 
series of simple motor tasks: 
1. Lie on the bed for 1 minute 
2. Rise from the bed and sit on a chair located beside the bed for 1 minute 
3. Perform Timed Up and Go Test (TUG) (65): “rise from a chair, walk three meters, turn around, walk 
back to the chair, and sit down”. 
4. Stand up from the chair and perform a series of activities: 
a. Stand (without move) for 1 minute (while standing, avoid communication with patient. 
Clinician stands in front of patient, not on patient's side, to avoid patient turning towards the 
clinician). The camera is placed in front of the patient, in order to capture postural 
abnormalities for the frontal plane. 
b. Walk for a distance of 5 meters, open the door (with the arm that wears wristband) and walk 
through the door, exit the room, go back in the room and close the door (repeat for 3 times, 
this should evoke freezing, if present). 
c. Two Minute Walking Test (66) 
d. Walk back to the room; 
5. Make a stop and drink a few sips from a glass of water (repeat the sequence: take the glass, drink and 
leave the glass for 3 times); 
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6. Stand (without move) for 1 minute. While standing, clinician avoids communication with patient. 
Clinician stands in front of patient, not on patient's side, to avoid patient turning towards the 
clinician. This time the patient is recorded from one side (the side recorded is the one where the 
patient is wearing the wristband), in order to capture any postural abnormalities for the sagittal 
plane; 
7. 360° turn test (67) clockwise + anticlockwise and record seconds and steps 
Cognitive Test Protocol 
The testing of the cognitive apps involved special care and provision in order to make the patient understand 
that did not testing him or her, the test regards the PD_manager application. Whenever the patient was blocked 
or felt insecure, we considered this as a mistake in the design of PD_manager apps. During the testing phase, 
which aimed to find out the errors in the apps and their design and therefore, it is very important that the 
patient does not feel ashamed. The patient should feel free to request changes if something is not intuitive, their 
requirements will make the application more feasible and therefore more functional for the patients 
themselves. For the validation phase a dashboard was implemented in order to facilitate the test. In the final 
design and implementation, the test will pop up in the smartphone of the patient as notification in fixed time 
points. For the initial validation during this task the test facilitator should simply open the test for the patient 
and ask him or her to take the test without additional instructions. Each test contains instructions in text, which 
are also reproduced with the text-to-speech feature (also make sure the volume level is adequate). 
1. Open a test for the patient 
2. Ask the patient to take the test without instructions or guidance and let him listen to the audio instructions on 
the phone. 
3. If the patient gets stuck or he/she takes the test in a wrong way, help him/her with brief suggestions or ask to 
retake the test explaining better how it works. In this case, use the table/ questionnaires “User Needs Interview 
(Part A, B), Cognitive App Usability Questionnaire, and PD Manager system Wearability questionnaire (devices) - 
to take note of the issues raised. 
4. Move to the next test. 
5. At the end of the administration fill the usability questionnaire. 
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Speech Test protocol 
 
A protocol for speech data collection was defined in order to collect data that will clearly represent the above 
mentioned symptoms and PD speech aspects. MDS-UPDRS 3.1 subitem (speech and language) scoring has been 
collected as clinical measure. Different tasks have been selected (Table 4) and each task is thought to evaluate 
the voice using different specific speech analysis software that aims to recognize whether symptoms are present 
or not: Speech Analysis deals with cognitive aspects of language whereas the Sound Analysis deals with motor 
aspects of speech. 
 
The audio recording was performed 2 times: one in ON and one in OFF state. In order to avoid the bias due to 
the repetition of the same questions during anamnesis, mood questionnaire or figure description, which would 
have resulted different, we split the sample of patients in two groups and assigned them randomly (see Table 5). 
Then two similar figures, used for speech assessment, were chosen. Group 1 performed anamnesis interview, 
figure description in ON state, whereas Group 2 performed mood questionnaire and figure description. In OFF 
state, groups inverted their tasks mutually. The task of sustained vowels was executed in both groups in ON and 
in OFF state as well as the MDS-UPDRS 3.1 scoring. Both groups underwent to the following procedures (shown 
in Table 5) during the voice recording. The procedure for sustained vowels recordings consists in 5 recordings of 
a sustained phonation. After activating the Smart Voice Recording App on the smartphone, the operator asks the 
patient to perform “AAAAAH” sounds that have to last for at least 3 -5 seconds. The repetition of these 
phonations is needed to obtain enough samples for the training of the algorithms. 
Table 4 Speech test tasks and relative type of analysis performed for Speech test Protocol 
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Table 5 Speech Test protocol and design 
 
Decision Support System (DSS) 
An important task of the PD_manager DSS is related to the change of medication. When the disease 
progresses and new symptoms emerge, it is essential to assess the patient’s situation and identify the need 
for changing the medication plan. In this case, the DSS should issue a warning to the responsible physician 
and provide reasons for it. Decision models have been developed to suggest whether or not to change the 
patient’s medication. The suggestion is made using data available in the PD_manager DSS for each 
individual patient, i.e. data about motor and non-motor symptoms, and epidemiological data. The 
approach used was expert modelling: by asking medical experts to formulate their rules for medication 
change, based on their medical expertise and experience, the technical partners have studied the possible 
combinations of DSS output. In this approach, decision-support models are developed in collaboration 
between the expert and the decision analyst, taking into account clinical guidelines and medical practice. 
The expert modelling approach was based on the method DEX (68). DEX is a qualitative multi-criteria 
modelling method. DEX models have a hierarchical structure, which represents a decomposition of some 
decision problem into smaller, less complex sub-problems. The hierarchy is formulated in terms of 
attributes and decision rules. All attributes are discrete (qualitative), and each attribute has an associated 
value scale that consists of words, such as {low, medium, high}. Optionally, scales are preferentially 
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ordered. Attributes in DEX form a hierarchical structure, i.e. a directed acyclic graph or, most often, a tree. 
Aggregation is defined in terms of decision rules, grouped in decision tables. Decision rules, while being 
formulated, are checked for completeness and consistency. All elements of a DEX model are acquired 
interactively from experts, i.e. no data mining is involved. The principal output studied is the so called 
yes/no model, that suggest if change or not change medication plan.  
Wearability and user’s needs interview 
After the last recording session, the patient is asked to fulfil the survey about the wearability of all the tools 
employed during the recording sessions (insoles, wristband, smartphone). The aim of this questionnaire is to 
detect any critical issue, raised by the patient, about wearing this kind of equipment. During the first recording 
session in ON state, the part A of the User need Interview has been administered to the patient, while during the 
last recording session in ON state, the part B of the interview has been administered. 
Educational Video Gallery 
One of the secondary objectives of the Project was the creation of a video gallery for patients and caregivers’ 
education, regarding disease issues and main symptoms. In a first phase, a series of symptoms or troublesome 
situations has been selected on the basis of the experience of the involved clinicians. The structure of each video 
was divided in a first part explaining the problem/symptom and in a second part with the possible 
tricks/solutions to cope with the specific problem/symptom. In a second phase a screenplay and a storyboard 
have been created for each educational video and they have been submitted to a subcontractor company, 
expert on video making. The video shooting has been co-directed by the clinicians involved. 
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Multicentric study 
The Multicentric Study is a clinical trial for the overall evaluation of the PD_manager mHealth platform, during 
which patients will try the PD_manager system at their home. The data captured from these recordings will be 
processed in the cloud backend and clinicians will evaluate the effectiveness and usefulness of the information 
acquired. The clinician partners involved will enrol patients that will be equally divided and randomly assigned to 
intervention group or Control group. The intervention group tests PD_manager system, while Control group fills 
symptom diaries: the results from both groups have been compared and analysed. In current clinical practice the 
gold standard for symptoms monitoring is represented by patients’home diaries (1): this modality is obviously 
not completely objective and difficult to carry out for some patients. The key point of the Project is to find an 
innovative, objective and easy-to-use tool for PD symptoms monitoring, so the system implemented during the 
Pilot study will be compared to patients’ diaries of symptoms, to verify if the experimental approach could 
represent a solution to satisfy patients’ and clinicians’ needs in terms of reliability, practicality and better care. 
The main scopes are to assess patients’ perspective of the PD_manager mHealth platform with respect to 
comfort, acceptability, ease of use and to assess the clinician’s perspective of the PD_manager mHealth platform 
with respect to usefulness of intervention/value of the information provided by PD_manager for decision 
making with respect to patient management; acceptability in clinical practice; confidence/reliability in the 
information. 
Study design 
The multicentric Study is a non-blinded parallel two group randomized controlled study (See Figure 5). The data 
obtained with this case-control study gave the possibility to have a clear comparison between the two groups. 
Blinding of participants, researchers and clinicians was not possible given the nature of the intervention. The 
randomisation has been necessary to exclude possible sample bias during the recruitment procedures, in 
particular concerning age, disease duration and stage and the ability in using electronic devices. The monitoring 
time has been set to 2 weeks. This period is closer to the possible exploitation path discussed in the Project, 
since the aim of the PD_manager is not to build a simple alerting system, but a tool that possibly allows to detect 
changes in symptoms (e.g. related to therapy changes or disease progression, when comparing two different 
monitoring sessions). In this perspective it has not been necessary to monitor the patients for longer to detect 
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changes induced by drugs and, on the other hand, even a monitoring of a few months is not a long enough 
session to detect disease progression. Also, from the analysis performed in Pilot Study, a duration of 2 weeks 
ensures the recording of a sufficient amount of data to be analysed. 
In the first phase the researchers have selected a list of possible participants and contacted patients and 
caregivers during clinical routine ambulatory visits or by phone calls, to verify the availability to participate. Once 
the subject has been enrolled by signing the informed consent, the researchers have started with the baseline 
data collection. At the same time, the randomization has been performed: participants, previously recruited 
have been assigned to the experimental group or to the control group by random cases selection. Participants 
have been informed of their group allocation immediately, and a researcher have provided the PD_Manager 
devices (intervention group) or the symptom diary (control group). The subjects assigned to the experimental 
group have been trained for the correct devices usage and have tried the PD_manager system at home. The 
subjects assigned to the control group have been trained only for the proper filling of home diaries, that have to 
be completed for three consecutive days during each of the two weeks (Houser Diary) or for just one day each 
week (PD Well Being Map). At the end of the two weeks, patient and caregiver returned to the Centre and will 
be asked to fulfil a questionnaire on acceptability of the study (different for each group). The researchers have 
collected the devices or the diaries and downloaded the data from the devices. This data and the data from the 
CRFs (Case Report Forms) have been stored online in B3D protected Servers, to be evaluated by the clinicians. 
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Patients selection and identification
Eligible patiente and caresrs are identified by clinicians. 
Information provided. Volunteers respond to research team
PD_manager group
Training for Devices usage
Training for App usage
2 weeks home monitoring 
with PD_manager devices
Informed consent
Baseline data collection 
Randomisation
Control Group
Training for Diaries usage
2 weeks home monitoring 
with diaries
Post trial interview
Figure 5 Multicentric Study design 
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Patients and clinical evaluations 
People with Parkinson’s and caregivers are recruited as dyads. The inclusion criteria for people with Parkinson’s 
were a diagnosis of idiopathic Parkinson’s disease according to the UK Brain Bank Criteria, an Hoehn & Yahr 
disease stage 3 in OFF state, the presence of motor fluctuations with an average of at least 2 hours of OFF state 
during the day and the presence of a live-in carer who is willing to take part in the study. 
The exclusion criteria for people with Parkinson’s were the presence of severe cognitive impairment (Parkinson’s 
Disease Dementia) or co-morbidities with stroke or other brain disease and the absence of a caregiver living with 
the patient. Each project Partner has identified his own modality to get in touch with an adequate number of 
patients, based on the total number of subjects allocated per clinical site participating to the study.  
For a complete and correct analysis of the recorded data, the sample’s clinical characteristics have to be 
precisely determined. Patients’ evaluation has considered the many aspects of each patient: disease severity 
(motor and non-motor symptoms), overall clinical status (with possible comorbidities) and pharmacological 
treatment (PD related medications and other drugs). Also, the cognitive status and the patient’s and caregiver’s 
propensity to use technological devices have been evaluated. To gather all this data and obtain a clear profile of 
each enrolled patient, several evaluation scales have been selected to be administered at the baseline 
evaluation: 
- MDS-UPDRS: this is the universally recognized and widely used rating tool in clinical management of 
Parkinson's Disease. It is divided in four sections covering 1) Mentation, Behaviour, and Mood, 2) ADL, 3) 
Motor sections, 4) Motor complications. MDS-UPDRS includes Hohen & Yahr scale for PD stage assessment 
(2). 
- NMSS (Non Motor Symptom Scale for Parkinson’s Disease): this scale evaluates severity and frequency of 
several common non-motor symptoms (69). 
- EQ-5D-5L, a commonly used generic measure of health-related quality of life that provides a utility index for 
use in economic evaluations (70); 
- PDQ-8, the short form of a Parkinson’s disease specific measure of health-related quality of life (71); 
- MMSE (Mini Mental State Examination): the most used clinical scale to perform a rapid and reliable 
evaluation of patients’ cognitive status (72). 
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- Questionnaire on technophobia: to evaluate dyad relation to technology, their opinions about possible use 
of technologic devices in daily life and their opinions about the PD_manager Project future implications on 
disease management (73). 
- Caregiver Burden Scale: to assess live-in carers’ perception of the disease (74) 
Baseline data have been collected by the physician by interview with patient and the carer and through 
reference to the clinical records. Data gathered includes:  
- for both members of the dyad: age, gender, education level, comorbidities, Global Attitude towards 
Technology Measure - Technophobia, Technology Acceptance Model Measure for E-health (75) 
- for the patients: comorbidities, disease duration, disease stage (Hoehn and Yahr scale), side of onset, 
current symptoms (tremor, bradykinesia, rigidity, dyskinesia), more affected side, Parkinson’s medications, 
MMSE score, MDS-UPDRS, EQ-5D-5L, PDQ-8 and the NMSS; 
- for live-in carers: Caregiver Burden Scale. 
 
Scale Patient Caregiver 
P
re
 in
te
rv
e
n
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o
n
 
MDS-UPDRS ✔  
NMSS ✔  
EQ-5D-5L ✔  
PDQ-8 ✔  
MMSE ✔  
Questionnaire on technophobia ✔ ✔ 
Zarit Caregiver burden scale  ✔ 
P
o
st
 
Acceptability Questionnaire (Devices/diaries) ✔ ✔ 
Table 6 Evaluations for Patients and caregivers 
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Participants have been notified in the information sheet that they are randomly assigned to one of two 
alternative ways of gathering more detailed information on Parkinson’s symptoms to help in the management of 
the condition (PD manager or symptom diary). Both patients and live-in carers have been asked at baseline, prior 
to randomisation, if they have a preference, and about their attitudes and expectations from each approach as 
this may affect the views they express after the trial. At the end of the 2 weeks, the dyads in both experimental 
and control group are asked to answer a Post Trial interview (Table 7) with an acceptability questionnaire 
regarding the devices (experimental group) or the home diaries (control group). 
Question number and topic Scale 
Q1 Ease of use 5 point Likert scale (1 “Very”- 5 “Not At all”) 
Q2 Time spent using the diary/device 5 point Likert scale (1 “less than 30 min”; 5 “more than 
2 hours”) 
Q3 Usefulness of Information 5 point Likert scale (1 “Very”- 5 “Not At all”) 
Q4 Usefulness for Symptoms self-management 5 point Likert scale (1 “Very”- 5 “Not At all”) 
Q5 Usefulness for Interactions with Doctor  5 point Likert scale (1 “Very”- 5 “Not At all”) 
Q6-A* Ease of use 1 “Very”; 2 “Little”; 3 “Not At all” 
Q6-B* Comfort 1 “Very”; 2 “Little”; 3 “Not At all” 
Q6-C* Usefulness for self-management 1 “Very”; 2 “Little”; 3 “Not At all” 
Q6-D* Usefulness for Doctor 1 “Very”; 2 “Little”; 3 “Not At all” 
Q7 Recommend - Device/Diary 1 “Yes”; 2 “Maybe”; 3 “No” 
Q8 Future use 1 “Yes”; 2 “I don’t know”; 3 “Definitively not” 
Q9 Preference - Device/Diary 1 “Diary”; 2 “I don’t know”; 3 “PD_manager” 
Q10 PD Manager VS Diary on treatment 1 “Both useful”; 2 “Both not useful”; 3 “Diary more 
useful”; 4 “PD_manager more useful”; 
Table 7 Post trial Interview. *for each subcomponent used (devices or diaries) 
Devices, Applications and Diaries 
The set of devices used in the Multicentric study is the same tested in the Pilot study: the Moticon® sensor 
insoles, the Smartphone and the Microsoft® Band wristband. Patients and caregivers have been trained for the 
correct usage of the devices, in particular how to wear the devices and how to charge the Smartphone and the 
Wristband using the battery charger provided. The patient had to wear the insoles inside a pair of shoes (the 
same pair for the entire period of intervention) and use them for the max possible time during the day. The 
patient also had to wear the smartphone inside the trousers’ pocket or in a small bag and the wristband on the 
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upper arm of the more affected side. The recording started automatically at 8 o’clock in the morning and 
stopped at 10 pm, so the patient had to put in charge the phone and the wristband every night. 
The mobile application developed within the project and used in the Multicentric study are: 
- PD_manager App: it’s the main application running on the smartphone which works as a gateway that 
collects motor and behavioural data (Cognitive Tests, Visual Analogue Scale Questionnaire, Nutrition). The 
App sends notifications to remember the patient to perform some test or to ask the patient if he/she has 
taken the medications on time. The patient can also perform tests whenever he/she wants, independently 
for the timing set. The researchers expressly avoided to explain in detail to the patients the app and test 
functioning to test if the system is comprehensible and easy to use. 
- Moticon® software: in this task we used an updated version of Moticon® software (Beaker), previously used 
in Pilot Study. Moticon® improved Smart-Recording modality to prevent memory overflow and created a 
Cloud interface to upload and share online the data gathered from patients. All this data is stored in a safe 
digital environment created by B3D partner. 
- Smart Lock App: in order to avoid incorrect usages of the Smartphones by patients during the Multicentric 
Study, we selected a free Android app (Kids Zone5) that allows to lock the access to all device settings and 
locks all the applications other than the ones that the patient is supposed to use. This App has to be 
installed in every Smartphone and activated with a 4-digit PIN, chosen by researchers. Besides restricting 
access to only Project’s approved apps and limiting patients screen time, Kids Zone’s app lock will also: 
prevent access to the Internet and block ad clicks, block in-app purchases or app installs from the Google 
Play store, re-lock the device automatically if it's rebooted, block patients from making phone calls or texts 
unless allowed to do such, block access to Home, selected notifications, system menus, all device settings 
and personal data. 
- Microsoft® Band App: this App is specifically developed by Microsoft® to connect Smartphone and 
Microsoft® Band. It provides actionable insights based on the rich data gathered from the band and any 
other fitness devices and apps the patient may use every day. Microsoft® Band App makes tracking 
personal activity easier, more insightful, and more holistic. However, in this phase of the Project, this App is 
only used to ensure a connection between the APIs for the collection of aggregated sleep and activity data 
and, it is not used to analyse data. 
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The diaries used for control group monitoring were: 
- Hauser diary (76): this is a validated instrument that allows the patient to record, in a dedicated form, his or 
her motor state every 30 minutes. This diary has been chosen because it is the current gold standard to 
monitor patient’s symptoms at home and it is frequently used also in pharmacological clinical trials to 
assess drug’s efficacy. 
- UCB (77) Parkinson’s Well Being MapTM: The Map is a free tool created to help patients to prepare for 
consultations with their healthcare team and help clinicians to better understand how living with 
Parkinson’s disease affects the subject. The Map allows to record and monitor the wide spectrum of 
Parkinson’s symptoms. It covers all aspects of Parkinson’s, so the patient can highlight the symptoms that 
are of most concern and list the most important questions to ask. 
The participant characteristics have been analysed in order to explore whether the two groups (PD manager and 
Symptoms Diary) were found to be homogeneous. Continuous scalar variables have been compared using T-
Test, while discrete/nominal and ordinal variables have been compared using Chi Square statistics. The methods 
used for data analysis of the main outcome of the study – opinion about acceptance, ease of use and usefulness 
– were mainly based on a Multinomial Regression in order to explore the difference of the opinions by weighting 
the effect of different clinical baseline characteristics which might have influenced the answer of the 
participants. Spearman correlations were run in addition to analyse the degree of accordance between Patients 
and Carers. Multinomial logistic regression is used to model nominal outcome variables, in which the log odds of 
the outcomes are modelled as a linear combination of the predictor variables. As predictor variable factors were 
selected all the items of the Post Trial Interviews ranging from Q1-Q5 and Q7 to Q10. As covariates, age and 
gender and attitudes towards technology for both patients and caregivers. Specific measures for patients and 
caregivers have been introduced in separate analysis. For caregivers: Zarit Caregiver Burden total score (High vs. 
Low Burden); for patients: PDQ-8 total score and Non-motor symptoms scale; UPDRS III total score. All the sub 
items of Q6 were analysed separately and grouped by focus area (ease of use, comfort, usefulness), and by 
subcomponent (smartphone, insoles, smart band, motor diary, non-motor symptoms diary). In order to compare 
the different subcomponent a non-parametric rank comparison was run (Friedman’s test). The significance level 
was set for all the analysis at p<.05. All the data have been analysed using IBM SPSS Statistics for Windows, 
Version 23.0. 2015. 
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The usage of the devices for all the patients that were recruited for the PD_manager Group have been evaluated 
in a patient per patient basis. For each patient of the PD_manager Group the respective graph depicting the 
usage of the wristband and the smartphone, as extracted from the gyroscope recordings of both devices, has 
been analyzed to find any possible correlations with his/her main characteristics (age, disease duration, 
education, technophobia) or with the clinical scales’ scores (TAMM, PDQ8, EQ-5D-5L, NMSS, Zarit, UPDRS), for a 
detailed insight regarding the implications and intrinsic motivations for the usage of the PD_manager mHealth 
system. 
Clinicians Study 
In order to get a feedback regarding the usefulness and the usability of the System, a study based on clinician 
perspective of PD_manager has been performed. A “Clinician App” has been developed by technical partners, 
based on clinicians’ suggestions. It has been conceived to output clear and understandable reports of the 
patient’s symptoms during the 2 weeks of trial. All functionalities of the app are designed to be smart, intuitive 
and to facilitate the clinician’s analysis of the data coming from the recordings. Moreover, the Clinican's App is 
integrated with the DSS System and is able to recognize specific patterns of symptoms that could be 
troublesome for each patient and report an alert to the clinician. From this point of view, the clinician’s feedback 
is crucial to establish if the information coming from the System could influence clinical decisions. Feedback was 
sought by means of a structured interview schedule on perceived usefulness to professionals: the clinicians were 
asked to comment on how easy it was to interpret the data generated by the devices and the symptom diary, to 
use this data in changing the treatment and care management of participants. Clinicians were also asked to 
report what action they would take (if any) for each patient following analysis of the data from PD_manager and 
the symptom diary, including changes in medications, management plan and referrals to other MDT (Multi-
Disciplinary Team) members. Also, the ease of use of the user’s interface of the Clinician App has been 
evaluated. To make a comparison between PD_manager system and symptoms Diaries we submitted to 
clinicians’ judgment the outputs coming from 3 selected patients monitored with PD_manager and 3 patients 
monitored with diaries 
42 
 
Methods  
For the evaluation of the Clinician App we have selected a group of clinicians, mainly neurologists, with various 
expertise, some of them even non-experts in PD management. Some of them were completely external from the 
PD_manager Project (external clinicians), others were the consultant neurologists of the patients enrolled, with 
a deeper knowledge on PD management issues and each patient clinical history and characteristics (internal 
clinicians). This last group of “more involved” clinicians was asked to evaluate the app also in terms of usefulness 
in clinical practice, not only from the usability point of view.  
The clinicians have been selected among those working within the Hospitals related to the clinical partners 
involved in the project. For external clinicians, focus groups of 3-4 clinicians have been organized. During this 
meeting, the aims and the main idea of PD_manager Project have been explained. Then each clinician was 
equipped with a tablet with the clinician app installed and the data coming from the recordings of three selected 
patients available for testing. The external clinicians were free to evaluate independently the app functionalities 
and to change or not the drug therapy referring on DSS suggestions. Scanned and anonymized copies of 
symptoms paper diaries collected by three selected patients from control group along with baseline clinical data 
were presented and evaluated by clinicians. The 6 cases (3 PD_manager + 3 diaries) have been chosen to be 
paradigmatic of fluctuating patients (high score on UPDRS IV). Finally, the questionnaire for Clinician App 
evaluation was administered. For Internal clinicians we performed the same test but with face to face interview 
and the questionnaire was finalised by Modified TAM2 scale. 
For the evaluation we administered to all clinicians a technophobia scale, to estimate affinity towards 
technology in general. Then each clinician was asked to fill a questionnaire regarding their previous experience 
in neurology, patients management, anti-PD drugs administration, mHealth systems eventually used in the past. 
To complete the task, specific evaluation scales have been selected and administered to all clinicians involved:  
- The Post-Study Usability Questionnaire (PSSUQ) is a 16-item survey that measures users’ perceived satisfaction 
with a product or system. Obtaining an overall satisfaction score is done by averaging the four sub-scales of 
System Quality (the average of items 1-6), Information Quality (the average of items 7-12), and Interface Quality 
(the average of items 13-16). The PSSUQ is highly reliable (.94) and is entirely free.  
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- The System Usability Scale (SUS) is perhaps the most popular standardized usability questionnaire, accounting 
for approximately 43% of published usability studies. It is a 10-item questionnaire designed to measure users’ 
perceived usability of a product or system. The SUS is highly reliable (.91) and is entirely free. The use of SUS is 
helpful to assess perceived usability, an added bonus to using the SUS is that recent psychometric analyses 
PD_manager project 16 shows that items 4 and 10 reliably measure the dimension of perceived “learnability”. 
Therefore, by measuring these items separately, it’s possible to gain an understanding of users’ perceived 
usability and learnability of the product or system being studied.  
The Technology Acceptance Measure (TAM) is an information systems theory that models how users come to 
accept and use a technology. The model suggests that when users are presented with a new technology, a 
number of factors influence their decision about how and when they will use it in terms of perceived usefulness 
and perceived ease-of-use. An update version of TAM, called TAM2 (3) extended the original TAM model to 
explain perceived usefulness and usage intentions in terms of social influence (subjective norms, voluntariness, 
image) and cognitive instrumental processes (job relevance, output quality, result demonstrability, perceived 
ease of use). The TAM2 model, was tested in both voluntary and mandatory settings. The results strongly 
supported TAM2. To prevent the presence of duplicate items (already tested in PSSUQ and SUS) and to avoid an 
excessively time-consuming questionnaire, we selected specific questions of the TAM2, focusing the attention 
on perceived usefulness of the System. The result is a TAM2 modified scale that will be administered only to 
those clinicians that were directly involved in the management of selected patients.  
Data Analysis that have been used are Cohen’s kappa for assessing the degree of agreement among physicians 
of the same group, and Multinomial Regression for the comparison analysis between groups and to explore 
evaluate the factors which may have influenced the outcome variables.  
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RESULTS 
Pilot Study 
A total of 20 patients with idiopathic Parkinson’s disease diagnosis have been included in the study. Due to the 
different prevalence of the disease between man and women, the sample was composed by 14 men and 6 
women. The mean age of this sample was above 65 and the mean disease duration was around 10 years, 
reflecting a sample of advanced PD patient. Cognition was almost preserved in all the patient and nobody 
reported severe impaired cognition (MoCA: 22.06 ± 5.63). Autonomy in executing daily life activity (ADL and 
IADL) was also not impaired for most of the subjects. Data that have been collected are shown in Table 8. 
 
Table 8 Demographic and clinical data collected for Pilot Study 
 
Patients included in this study presented a variety of motor symptoms: ~30% of the sample had motor 
fluctuations (frequent change from ON and OFF state) during the day and only 6/20 had dyskinesia. The whole 
sample showed bradykinesia and tremor pattern, and the majority had freezing of gait episodes. Falls occurred 
frequently only in 3 patients, 8 had rare episodes, while the others did not. Only 1 patient was treated with 
Levodopa intestinal infusion, and 3 had a STN-DBS. 
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Table 9 Main motor features and clinical characteristics 
 
A total of 140 out of 160 (expected) session were recorded. Drop-out were due to excess of fatigue experienced 
by the patient, or because motor symptoms were highly severe, mainly during recordings in Off state. Here we 
report MDS-UPDRS data scoring during sessions grouped by Motor State (ON State vs. OFF state). We found 
consistent data within patients, congruently with the expectations of ON vs OFF changes (Table 10). 
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Variables OFF State  ON State     
 
M SD 
 
M SD  df F/X2 p 
UDPRS item 3.3b Rigidity severity R 1.20 0.88 
 
0.65 0.61  1 17.5 .000 
UDPRS item 3.3c Rigidity severity L 1.29 0.91 
 
0.71 0.82  1 15.015 .000 
UDPRS item 3.4a Finger tapping R hand 1.55 0.90 
 
1.20 0.83  1 5.29 .023 
UDPRS item 3.4b Finger tapping L hand 1.82 0.86 
 
1.49 0.83  1 4.998 .027 
UDPRS item 3.10 Gait 1.73 0.87 
 
1.12 0.74  1 19.46 .000 
UDPRS item 3.17a Tremor Severity R Arm 0.45 0.85 
 
0.19 0.43  1 5.394 .022 
UDPRS item 3.17b Tremor Severity L Arm 0.65 0.87 
 
0.20 0.58  1 12.516 .001 
UDPRS item 3.17c Tremor Severity R leg 0.30 0.70 
 
0.07 0.26  1 6.521 .012 
UDPRS item 3.17d Tremor Severity L leg 0.36 0.84 
 
0.13 0.51  1 3.867  .05 
2min Walk Test distance  91.37 48.09 
 
113.73 49.48  1 6.35 .013 
360Turn time R 14.26 16.05 
 
6.03 2.91  1 15.735 .000 
360 steps R 14.73 7.61 
 
10.03 4.09  1 17.229 .000 
2minWALK speed 0.76 0.40 
 
0.95 0.41  1 6.35 .013 
TUG sec 41.10 53.26 
 
15.16 4.32  1 14.619 .000 
360Turn time L 26.98 94.04 
 
6.25 3.42  1 3.012 .085 
360 steps L 13.62 6.75 
 
10.23 4.50  1 10.012 .002 
Dyskinesia (Y/N) (64 No; 4 Yes) 
 
(42 No; 28 Yes)  2 23.785 .000 
Table 10 Clinical evaluations performed during Motor recording Protocol 
Gait, Freezing of Gait, Tremor, Dyskinesia and Bradykinesia have been the main motor features studied. Gait and 
FOG have been evaluated using data coming from the insoles, while tremor and dyskinesia have been assessed 
analyzing data gathered with the wristband. Bradykinesia have been evaluated combining data coming from all 
the devices. All the raw data analysis and the signals processing have been performed by technical partners’ 
engineers.  
Gait and Freezing of Gait 
To improve the step detection for Parkinsonian gait, the data of several patients was manually augmented by 
labelling steps events (heel strike and toe off events), thereby distinguishing walking phases from non-walking 
phases. Then, the algorithms and heuristics for detecting steps where adapted until a satisfactory success rate 
was achieved. The algorithms are based on both the pressure and the acceleration data measured by the sensor 
insoles. To further optimize results, the algorithm parameters underwent an automated parameter variation 
procedure which optimizes the parameters based on a cost function. This cost function penalizes false-positives 
and false-negatives of the step detection result. In summary, the modification of the step detection resulted in 
an algorithm which is capable of correctly identifying most of the steps in Parkinsonian gait data. Nevertheless, 
in few cases of severe gait impairment, a significant number of steps were not found by the software. Several 
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differences between Parkinsonian gait and normal gait were noticed, for example the shape of the total force 
curve during the step cycle had a different distribution, also the average gait line was shorter and the pressure 
distribution on the forefoot appeared to be different. Another example is the gait line length: since PD patients 
tend to walk on the fore foot without bringing significant load on the heel, it was assumed that the average gait 
line length is shorter as the disease severity increases (Fig. 7). The average gait line length for a UPDRS gait class 
of 3 is about 25% of the insole length, which is about half the gait line length for a score of 0.  
 
 
Figure 6 Gait line length grouped for each UPDRS Gait subitem score 
 
Also, the total force curve depicted in Fig. 8 shows two peaks, which result from heel contact and foot off 
(patient with almost no visual gait impairments). In distinct Parkinsonian gait, significantly different total force 
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curves were observed, such as a missing second peak and missing local minimum between the peaks
 
Figure 7 Total ground force for left and right foot in a) normal gait patient and b) patient with gait impairment 
 
As an example for the features computed from the local peaks of the ground contact force curve, Fig. 9 shows 
the statistics of the average time between heel strike and the local force minimum between the two peaks (0 is 
assigned if second peak is missing) depending on the UPDRS gait class. In particular, the results for a UPDRS gait 
class of 3 clearly stand out against less severe scores. 
 
Figure 8 Average time between heel strike and local minimum force, grouped for UPDRS gait subitem score 
  
a) 
b) 
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An interesting observation is the fact that Fig. 7 and Fig. 9, both showing a feature which exists for both left and 
right foot, show similar results for left and right. This validates the computation of these features and suggests 
that the suspected statistical correlation with the UPDRS gait class in fact exists, even though the number of 
patient and the corresponding datasets is relatively low. A total number of 85 features were computed for all 
datasets. Some of them characterize the overall walking behaviour (e.g. cadence), others are parameters specific 
the left and right foot side (e.g. the gait line length). The 85 features include parameters which compare the left 
and right foot, e.g. the difference of the gait line length between left and right. All these features have been 
studied with correlation matrix and a machine learning analysis have been performed to find correlations 
between specific parameters and to find characteristics capable of UPDRS subitem 3.10 (gait) estimation. The 
methods do not allow for a direct detection of ON/OFF states essentially because the gait of a patient with low 
disease severity in OFF state can be “better” than the gait of a patient with high disease severity in ON state. 
However, looking at individual patients, the estimated UPDRS gait item can be a valuable characteristic for 
tracking the disease status, indicating whether the patient condition improves or deteriorates. Looking at the 
task of separating patients without gait impairments (class 0) from patients with gait impairments (class 1 and 
higher), the accuracy is 91%, the sensitivity is 97% and the specificity is 50%. The low value for the specificity is 
also caused by the fact that only few measurements with a UPDRS gait item of 0 exist in the data set. The most 
important feature turned out to be p_mid_stance_asymmetry, which describes the difference in the pressure 
distribution between the left and right foot during the mid-stance phase. 
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Figure 9 Screenshot of Moticon® Software showing analysis of pressure distribution during gait cycle 
 
Regarding FOG detection, the overall procedure for working with the data gathered from the sensor insoles 
included the implementation of an automated extraction of FOG annotations from the data and computation of 
the overall FOG duration. An expert clinician reevaluated the video recordings and annotated every single FOG 
episode. For each FOG episode the clinician set start time, stop time and gave a score: FOG < 5 seconds = 
severity 1; FOG <10 seconds =severity 2; FOG >10 seconds (or FOG+imbalance/risk of fall) = severity 3. Then an 
inspection of the raw data in all possible parameters (pressure distribution, center of pressure, total force, and 
acceleration) have been performed with respect to patterns that are symptomatic for FOG periods. The 
following steps were computation of features reflecting these patterns and definition of a criterion function 
which is capable of indicating FOG. Finally, we found an optimal threshold on the criterion function, to separate 
FOG from non-FOG episodes and we calculated the accuracy of this approach with respect to the experts’ 
annotations. In particular, all available FOG episodes have been analyzed so as to understand the motion signals 
during these episodes, and their difference to non-FOG signals. The automated assessment of FOG was tested 
against the annotated FOG events which are based on the observations of clinical experts. This verification was 
carried out in two steps: First, a direct comparison between the annotated FOG duration and the estimated 
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(detected) FOG duration for each measurement. Second, a threshold was applied on the detected FOG duration. 
All analyses have been performed using Moticon® Software for event tagging and signal processing, IBM SPSS 
Statistics v23.0 for descriptive and inferential statistics and MATLAB for the classification algorithm. 
For the purpose of FOG detection, a clinician annotated all FOG events by looking at the video. Replaying the 
data along with the video and setting the start/stop markers was carried out using the Moticon® software. A 
detailed analysis of false-positive events (time periods which were detected as FOG while not being annotated 
as FOG event) showed that, in several of these cases the data misses FOG event annotations. Apart from some 
data periods with missing video, this is due to the fact that one of the FOG-provoking tasks was to leave the 
patient’s room through a door, close and re-open the door, and then walk back into the room. Of course, FOG is 
not visible in the video while the door is closed. The algorithm was developed to match the total time span of 
FOG, and not to exactly match annotated start/stop events. The annotated FOG durations per measurement 
were between 0 and 417 seconds, with an average of 33 seconds. Out of all measurements, 38% contained 
annotated FOG events. In OFF state, the average duration of annotated FOG events was 61 seconds, compared 
to 7 seconds for ON state measurements. The FOG duration of measurements with long annotated FOG 
durations was generally underestimated, while in general the correlation with the true FOG duration was 
considered good enough for data mining purposes. Measurements with a detected FOG duration of more than 
rT = 0.7% of the measurement duration (optimal threshold obtained from parameter variation) were considered 
to be FOG measurements containing FOG, while those having less than rT = 0.7% of detected FOG were 
considered to be non-FOG measurements. This threshold filters out short-term motions which are falsely 
detected as FOG. As a result, 90% of the measurements have been correctly detected as either having FOG or no 
FOG. The false-positive rate was 6%, the false-negative rate 4%. 
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Figure 10 Correlation between automatically detected FOG duration and duration annotated by clinician 
Tremor 
For Tremor assessment the Microsoft Band have been employed, equipped with both accelerometer and 
gyroscope. The accelerometer was used mainly for hand posture/rest detection, whereas the gyroscope was 
used for tremor detection and assessment. The proposed method consists of  
1. Signal Pre-processing: Three signals are produced from filtering (FIR) of the original gyroscope (G) and 
accelerometer (A) signals: 1. A1: Low-pass (< 𝑇𝑓) gyroscope signal mainly used for tremor detection. 3. 
G2: High-pass (> 𝑇𝑓) gyroscope signal mainly used for tremor detection and amplitude estimation. 
2. Tremor Detection: Both detection and amplitude estimation are based on a 3-second window. Typically 
tremor has a dominant frequency on the 3.5-8 Hz frequency band, whereas voluntary movement 
frequency range is below 2.5-3 Hz. A number of features are extracted including the energy of the G1, 
G2 signals and their ratios compared to the whole signal energy. The results of the machine learning 
algorithm for tremor detection showed an accuracy of 94%. 
3. Tremor Amplitude Estimation: In order to calculate the tremor amplitude, the G2 signal is used, which 
includes the tremor related frequencies. The UPDRS Tremor severity is divided in four scales based on 
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maximum observed tremor amplitude: i) 0-1.5, ii) 1.5-3, iii) 3-10 and iv) >10 cm. The UPDRS scale is 
approximated by a fuzzy linear function. For each recording the tremor UPDRS amplitude is estimated 
by the 90th percentile of the 3-second window tremor amplitude estimations and the tremor UPDRS 
constancy is estimated by the percentage of 3-second windows detected with tremor. The Pearson 
correlation between the estimated UPDRS tremor amplitude and expert is R=0.95 (Fig. 11a). Similar 
results are obtained for tremor constancy (R=0.97) as depicted in Fig. 11b. From the patients with 
tremor, two have also posture tremor with similar severity. 
  
 
4. ON-OFF differences: Using the developed tremor detection algorithm, tremor amplitude and constancy 
are evaluated for ON and OFF periods. For a subset of 5 patients (Fig. 12) with significant tremor, 
constancy is found statistically higher (P=0.0074) in OFF periods. Tremor amplitude is also higher but it 
does not reach statistical significance (P=0.12). More experiments are needed to have a statistically 
significant conclusion regarding changes of tremor amplitude and constancy in ON and OFF periods. 
Figure 11 Comparison of a) Rest UPDRS Tremor amplitude (T.A.) estimation and b) UPDRS Tremor constancy (T.C.) estimation with experts 
annotation 
a) b) 
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Figure 12 Tremor constancy in On and Off state for 5 patients 
Dyskinesia 
Dyskinesia consists of frequent wide involuntary movements of limbs, trunk or head, so the first goal was to 
measure the long term constancy and energy of patients’ movements. At that point the algorithm must 
discriminate intense dyskinesia movements from voluntary movements. Normal intense voluntary movements 
with a long duration tend to be more regular than dyskinesia driven ones, so the algorithm used this feature to 
detect and analyze separately long “intense” movements with different patterns of constancy. Another 
important aspect is the discrimination between dyskinesia and tremor. Usually these two symptoms do not 
appear simultaneously because they are manifest in On or in Off state respectively, in fact dyskinesias appear as 
a side effect of excessive L-dopa blood concentration, while tremor appears when the medication effect is low 
(off state). However, since we could not exclude a priori the compresence of these two symptoms, the tremor 
detection algorithm have been used to discriminate windows with tremor. Also better results can be achieved in 
terms of dyskinesia detection if walking is excluded from analysis (using wrist accelerometer). Walking periods 
have been considered in order to exclude those time regions from input signals analysis for dyskinesia detection. 
The PD Manager Dyskinesia evaluation method is presented in Fig. 13. The methods for each signal window 
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consists of: i) tremor detection, ii) signal pre-processing, iii) detection of long continuous movements (LCM), iv) 
feature extraction from both LCM and whole signal window v) dyskinesia detection and severity estimation.  
 
Figure 13 Dyskinesia evaluation method 
 Around 40 hours of home recordings from several patients have been employed for the evaluation of the 
method, including ~8 hours of dyskinesia. Dyskinesia detection accuracy in PD patients varies from 88% when a 5 
minutes window estimation is used to a 98% for a 30 minutes window. The dyskinesia classification between 
slight/mild and moderate/severe had an accuracy of 0.92 for 5 minutes window estimation, using only one 
feature. 
Bradykinesia 
All the signals where tagged according to the activity that was performed by the patient: walking, drinking, 
sitting, lying and standing. This process was repeated for each session and state (ON, OFF). Based on this 
information the whole sessions were split depending on the activity. The performance of each sensors from each 
device was tested independently. The signal used were resultant vector of the accelerometer and resultant 
vector of the gyroscope from the smartphone; resultant vector of the accelerometer and resultant vector of the 
gyroscope from the wristband; resultant vector of the accelerometer, central pressure values and total force 
values both from the left and right feet from the sensor insoles. Since the bradykinesia is a symptom linked with 
the movement, the data regarding walking and hand movement were processed to extract a set of features. For 
the extraction of these features the signals should be split again using a sliding window where the features are 
extracted. Since the state-of-art works used windows length from 3 to 10 seconds, three different windows 
lengths were used in this case to explore the performance of the classifiers according to this value, particularly, 
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5, 15 and 30 seconds were tested using a 50% overlap between each window. Apart from the automatic 
assessment of the bradykinesia based on the signals coming from the different devices available in the 
PD_manager platform, an Android application has been developed to implement the Finger Tapping Test and 
the Alternative Finger Tapping Test which are two tests highly used in the current clinical practice. The 
participant must tap on the area as fast as he/she can during 10 seconds. The participant can start whenever 
he/she wants. When this test ends, the alternate finger tapping test will be automatically loaded. For each test, 
several parameters have been registered: Timestamp, i.e. start time of test; Test duration (ms), i.e total length of 
test in milliseconds; Total taps, i.e. total number of taps during the test; Error taps, i.e. number of no alternately 
taps during the test; Average time between taps (ms), i.e. mean of times between two consecutive taps in 
milliseconds; Standard deviation of time between taps (ms), i.e. standard deviation of times between two 
consecutive taps in milliseconds; Median time between taps (ms), i.e. median of times between two consecutive 
taps in milliseconds. 
 
Figure 14 Screenshots from finger tapping App 
 
The individual performance of each sensors available in the mHealth platform has been studied. Moreover, the 
effect of different windows lengths has been explored continuing the state-of-the-art works. In general, better 
performance has been achieved using larger windows lengths and using the insoles sensors. The best accuracy 
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result was achieved with the Center of Pressure (CoP) sensor from the insoles with a 30 seconds length window 
(81.66% accuracy). Since bradykinesia is a symptom linked with motion, two different scenarios have been 
studied: 1) signals from the smartband sensors during hand movements and 2) signals from all the sensors 
during walking movements. This second scenario provided the better results for the bradykinesia assessment. 
Moreover, two approaches have been explored, the first one, solving each UPDRS value as class of the 
classification problem and a second approach grouping the UPDRS values in the following three classes: None 
(UPDRS = 0), Mild (UPDRS = 1 & UPDRS = 2) and Severe (UPDRS = 3 & UPDRS = 4). The second approach provided 
better results achieving up to 81.46% of accuracy in the detection of the aggregated UPDRS category. 
Cognitive App test results 
All patients underwent the cognitive monitoring delivered via smartphone, although not all of them completed 
the whole protocol for several reasons. First, small technical issues arisen during the study have been adjusted 
along the way The Usability questionnaires, indeed, have highlighted critical issues related to the clarity of the 
instructions, the duration of the whole assessment, type of test and task that require to be redesigned. On the 
basis of this feedback the app has been modified with general improvements. The Text To Speech (TTS) function 
has been redesigned to increase the compatibility with more Android Devices, also the default pitch and speed 
were modified, using a slower speed and lower pitch according to the feedback from some of the users. The 
application has been modified to be more stable, each single test has been analyzed more accurately and also 
the feedback from the pilot study helped to detect some breaking points that were corrected and fixed. The 
visual and auditory feedback of the tests has also been included in some of the tests that did not show it. The 
stack of screens has been simplified and some use cases based on sequential actions leading to unexpected 
behavior were corrected as well. A specific layout for tablets was also implemented in order to improve the user 
experience and ensure the compatibility on this kind of devices. 
Speech analysis results 
speech data from four patients (N=4) was collected in ON and OFF conditions. The Synthema company engineers 
(now part of Live corp.) have tested four different machine learning algorithms to classify on or off condition 
based on sustained vowels test. The results showed that “Random Forest” algorithm has an accuracy of 99% in 
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discriminating between on and off condition and also 99% in detecting the correspondent UPDRS subitem 3.1 
score.  
For the Automated Speech Recognition (ASR) task, Synthema has provided speech to text technologies, using an 
innovative Speaker Independent ASR engine for audio transcription, which has been adapted to the project 
needs. In fact, within PD_manager the speech to text system must be able to operate according to a model of 
language which is not “usual”, but enriched through the knowledge of the language production process typical 
of Parkinson’s disease. A speech corpus (2 hours and 13 minutes of audio recorded from 21 patients) containing 
speech deficits typical of Parkinson’s disease has been annotated to train an acoustic model. ASR was used 
for transcription and Text Mining algorithms to analyse the transcription in order to extract:  
• Formal characteristics of the speech structure (speaking rate parameters) through a reading test 
• Sentiment information (mood oscillations) through a spontaneous speech test 
• Semantic information (to evaluate semantic knowledge of concepts, addressing conceptual attributes 
and conceptual relations) through a logical test in speech modality 
Decision Support System (DSS) 
Several expert models have been created. Models are composed of three subtrees of criteria, representing 
indications for medication change based on Motor and Non-Motor symptoms, and Epidemiologic data. The 
latter is used to determine if the patient’s lifestyle is active or passive, which may largely affect the 
prescribed medication therapy. The majority of other attributes are binary, taking two values: normal and 
problematic. The latter represents the state of the corresponding symptom that is troublesome for the 
patient and may require a change of medication. The resulting models have been tested on PPMI database 
(78) and on the answers of 27 external clinician based on 15 real cases. The best accuracy on PPMI data in 
providing ‘right’ suggestions for given inputs, in accordance with medical guidelines, was 52.5% for “Model 
I”, while comparing the models to experts’ answers, the best accuracy found was 89.72% for “Model C”.  
Wearability and users’ needs interview 
The patients recruited have been asked to answer questions regarding comfort issues related to usage of the 
devices in Pilot study. All the devices resulted to be safe, comfortable and well tolerated, at least for the short 
duration of the measurements performed during Pilot Study. 
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Educational video gallery 
With the help of a professional video recording and editing Studio, it has been possible to produce educational 
videos aimed to inform the users about the disease, explaining and visualizing the major symptoms and 
explaining good practices required for everyday management of the disease. The targets were patients and their 
caregivers, in order to suggest solutions and tricks to simplify the everyday life of a Person affected by PD. The 
result is the creation of 11 educational videos, in each one of them a crucial aspect of PD is treated: they 
represent an accurate selection of the most frequent, disabling and possibly dangerous symptoms/situations 
that a person suffering from PD need to recognize and surely will be found to cope with. (instability an falls, FOG 
and cueing strategies, tremor, orthostatic hypotension, personal hygiene care, writing, impulse control disorder, 
swallowing problems, hypophonia, depression, REM behaviour disorders). The educational modules also have 
the important function to guide the patient via a remote support. In fact, videos can be viewed remotely, the 
videos are playable on many devices and this methodology can easily meet the different needs of patients. 
 
Figure 15 Screenshot from one of the educational videos produced 
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Multicentric Study 
 
A total number of 136 patients and 136 caregivers have been enrolled and tested, 73 dyads tested the 
PD_manager System, while 59 were assigned to the control group with home diaries. Only 4 dropouts have been 
observed. The Interviews collecting the opinions about the 14 days’ intervention period have been analysed and 
compared in order to assess the acceptance, ease of use, usefulness of information of the PD_manager system 
and the Symptoms Diary. More than 3,500 hours of recording have been collected and analysed case by case to 
evaluate the compliance to the PD_manager system and to assess the methods for symptoms evaluation 
developed within the whole project.  
The mean age of participant was 67.91, and the 65.9% of the participants was above 65 years old. Gender ratio 
resulted in 63.9% of men and 36.1% of women, such ratio was also found to not be different between the two 
experimental group. Education level was normally distributed with a mean 10.28 (±4.98), years and a standard 
deviation of 4.97. The level of Technophobia was prominently composed by not technophobic subjects (45.5%), 
whether the highly technophobic subjects were just the 11.4%; the Technophobia level resulted also 
homogeneous between groups. Concerning the clinical aspects, the sample resulted composed for the 80.8% by 
patients with an H&Y stage ≥ 3 in ON state. The mean UPDRS total score was 58.97 (±3.73), UPDRS III M=29.56 
(±16.23), UPDRS IV M=6.10 (±3.72). The sample resulted also with a disease duration mean of 9.43 (±4.68), with 
the 79.3% of subjects above 5 years from symptoms onset. Caregivers sample resulted homogeneous as well. No 
significant differences were found in any of the variables examined. The overall mean age of caregivers sample 
was 60.99 (±16.43) for the, gender ratio (43 males; 79 females) was somehow inverted if compared to the group, 
indicating a consistent percentage of husbands and wives as shown in “Relationship with patient” (87.2% 
husband/wife; 8.3% friend; 4.5% other). The level of education was 11.30 (±5.42). Considering a cut-off of 17/48 
for severe/high burden, the Zarit Caregiver Burden scale score resulted slightly lower the mild burden threshold 
with a mean value of 8.90 (±6.41) (7.94 ± 5.55 in PD_manager group and 9.81 ± 7.22 in Diaries group). The 
attitudes toward technology were in large part (72.2%) above or equal to score 3 and 4 (low technophobic, not 
technophobic). 
A group comparison has also been performed in order to find possible significant differences between the two 
groups (Table 11). The two groups were found homogeneous, for all variables. In PD_manager group, only 18.1 
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% has an H&Y stage <= 2 measured in ON condition, in Diaries group this percentage is even lower (8.9%) with a 
great majority of patients with an H&Y stage of 3 (71.4% of patients in Diaries group): this reflects a good 
selection of patients, representing a sample of moderate-advanced PD, even if collected ON state. In 
PD_manager group and Diaries group, the percentage of subjects older than 65 where respectively 58.1% and 
63.8%, with a mean age of 69.24 years in PD_manager group and 66.67 years in Diaries group and a mean 
disease duration of 9.24 ± 4.30 years in PD_manager group and 9.73 ± 5.11 years in Diaries group. This is again a 
good representation of typical moderate-advanced PD patients. Despite the age, only 7.7% and 13.8% of 
patients respectively in PD_manager group and Diaries group, describe themselves as highly technophobic, with 
a great majority of subjects that is mild or not technophobic. The most common symptoms at the disease onset 
were tremor and rigidity for both groups. UPDRS Part III (measured in ON status) mean score was 28.42 ± 15.06 
in PD_manager group and 30.56 ± 17.43 in Diaries group, which are values compatible with H&Y stage 2 while 
UPDRS IV score were respectively 5.86 ± 3.95 and 6.25 ± 3.40, that underline how our sample presents an higher 
score on motor complications UPDRS subitems, comparable with scores typical for H&Y stage 3 . This condition 
seems to be mainly related to overall time spent in OFF and motor fluctuations rather than time spent with 
dyskinesia. In fact 53.4% of patients in PD_manager group and 58.9% in Diaries group has no dyskinesia, while 
80.8% and 82.2% respectively in PD_manager and Diaries group has a score of 1 or 2 in UPDRS subitem 4.3, that 
means up to 50% of waking time spent in OFF status. Moreover, 74% of patients in PD_manager group and 86% 
in Diaries group has an UPDRS subitem 4.4 > 0, this means that fluctuation of symptoms has a negative impact 
on daily life activities in the majority of patients. PDQ8 results show a mean value of 40.79 ± 20.75 in 
PD_manager group, adequate for patients with H&Y stage of 3 and 47.75 ± 22.71 in Diaries group, which is a 
higher value, more adequate for patients with H&Y stage of 4. 
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PD_manager Group Diaries Group 
 
 
Mean SD Frequencies Mean SD Frequencies p value 
N 
  
75 
  
57 .141 
Age 67.94 8.82 
 
67.88 8.88 
 
.966 
Gender (M; F) 
  
(47;28) 
  
(37;20) .790 
Education 10.71 4.69 
 
11.94 4.18 
 
.155 
Disease Duration 9.22 4.35 
 
9.73 5.11 
 
.494 
Hoehn &Yahr stage  2.7 0.6 
 
3.0 0.5 
 
.141 
Height 169.16 8.95 
 
169.74 9.05 
 
.737 
Weight 75.13 12.57 
 
76.19 16.31 
 
.700 
MMSE 28.46 1.81 
 
28.21 1.69 
 
.473 
LEDD 738.06 518.46 
 
785.88 649.41 
 
.231 
DAEDD 221.44 145.51 
 
185.15 84.55 
 
.204 
UPDRS_I_Total 10.00 5.20 
 
10.84 5.43 
 
.421 
UPDRS_II_Total 9.88 6.76 
 
11.44 8.05 
 
.283 
UPDRS_III_Total 26.36 14.28 
 
29.58 18.61 
 
.316 
UPDRS_IV_Total 5.38 3.76 
 
6.36 2.97 
 
.155 
UPDRS_Total 51.87 24.39 
 
58.22 30.31 
 
.237 
PDQ8 Total 38.33 19.91 
 
44.61 22.12 
 
.126 
TAMM_Total 22.09 10.35 
 
24.02 12.34 
 
.384 
Technophobia 
(HT; MT; LT; NT) 
  (8;15;19;33)   (9;8;14;26) .886 
Table 11 Group comparison – Patients (MMSE: Mini Mental State Examination; LEDD: Levodopa Equivalent Daily Dose; DAEDD: Dopamin 
Agonist Equivalent Daily Dose; HT: highly technophobic; MT: mid technophobic; LT: low technophobic; NT: non technophobic) 
 
  PD_manager Group Diaries Group   
 
Mean SD Frequencies Mean SD Frequencies p-value* 
Tested     75     57 
.141 
Gender (M; F)     (27;42)     (16;37) 
.533 
Age 59.91 18.67   62.43 12.91   
.420 
Relation with Patient 
(Family; Friend) 
    (67;5)     (48;6) 
.656 
Education 11.64 5.16   10.83 5.78   
.438 
Preferred Group 
(PD_manager, Both, Diaries) 
    (41;14;4)     (23;12;11) 
.066 
Zarit Caregiver Burden 
Scale 
7.96 5.54   10.0 7.22   
.135 
Technophobia  
(HT; MT; LT; NT) 
    (4;9;21;34)     (7;13;12;19) 
.115 
TAMM Total 23.93 12.36   24.78 12.36   
.715 
Table 12 Group comparison – Caregivers (HT: highly technophobic; MT: mid technophobic; LT: low technophobic; NT: non technophobic) 
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Post trial interview 
In the next section the results coming from the comparison of PD_manager Group and Diary Group (Control 
Group) opinions, after the 2 weeks intervention period, are reported. For each Question of the Post Trial 
Interview, the results for multinomial regression analysis are displayed in charts and tables including the 
statistics of the tests performed. As previously described in Data Analysis section, the Multinomial Regression 
Model took into account as predictor variable factors were selected all the items of the Post Trial Interviews 
ranging from Q1-Q5 and Q7 to Q10, in relation to the factor Group (PD_manager, Symptoms Diary). As 
covariates, age and gender and attitudes towards technology for both patients and caregivers. For caregivers: 
Zarit Caregiver Burden total score (High vs. Low Burden); for patients: PDQ-8 total score and Non-motor 
symptoms scale; UPDRS III total score. From a first run of the analysis, we observed no influence of any covariate 
in explaining the regression model. The randomization process resulted in a homogeneous composition of all the 
variables chosen as covariate, producing a non-significant effect of the model fit. So, the analysis was run 
excluding the above-mentioned covariates. 
The regression model for PTI Question 1 – “How easy / difficult has it been for you to use the PD_Manager 
system?” – turned out to not fitting the parameters used as covariates. Although, the answers “Very easy” 
(B=20.156; W=871.00; df=1; p<.001) and “Quite easy” (B=20.110; W=775.50; df=1; p<.001) resulted significantly 
associated to PD_manager group. After the re-run of the analysis, the effect for “Very easy” (B=20.156; 
W=871.00; df=1; p<.001) and “Quite easy” (B=20.110; W=775.50; df=1; p<.001) were confirmed to be 
significantly associated with PD_manager group. 
 
Figure 16 PTI Question 1 - Easy to use 
 
0% 20% 40% 60% 80% 100%
PD manager
Diary
How easy / difficult to use
Very easy
Quite easy
Neither easy
Quite difficult
Very difficult
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The regression model for PTI Question 2 – “About how long each day did you spend using the PD_Manager 
devices?.” – turned out to not fitting the parameters used as covariates. However, after the re-run of the 
analysis, excluding the non influencing covariates, the answers “Less than 30 min” resulted significantly different 
for the PD_manager group and inversely related to the Control Group (B= -2.25 W=4.01; df=1; p=.045), meaning 
that the ratio of the answer changes and revert itself for answer that goes from “30 min to 1 hour” to “More 
than 2 hours. 
 
Figure 17 PTI Question 2 -Time spent using monitoring system 
The regression model for PTI Question 3 – “How helpful do you think the information from the PD_Manager 
devices/Diary has been in helping your doctor to plan your treatment?” – didn’t show any significant differences 
between the two groups (X2= 8.630; df=9; p=.472). Moreover, no differences were found between the different 
factors, showing the same rating for both PD_manager group and Symptoms Diary Group. 
 
Figure 18 PTI Question 3 -Perceived hepfulness 
The regression model for PTI Question 4 – “How helpful do you think the PD_Manager devices/Diary have been 
in helping you to manage your symptoms?” – didn’t show any significant differences between the two groups 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PD manager
Diary
Time spent by participants
Less than 30 min
30 min to 1 hour
Between 1 hour and
1.5 hours
More than 2 hours
0% 20% 40% 60% 80% 100%
PD manager
Diary
Perceived helpfulness
Very helpful
Quite helpful
Neither helpful
Not helpful
Not helpful at all
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(X2= 7.010; df=9; p=.636). No differences were found between the different factors, showing the same rating for 
both PD_manager group and Symptoms Diary Group. 
 
Figure 19 PTI Question 4- Perceived helpfulness in self-managing patient’s symptoms 
The regression model for PTI Question 5 – “How did the PD_Manager system affect the discussions with your 
doctor about your symptoms and treatments?” – turned out to not fitting the parameters used as covariates, so 
no differences were observed. The model didn’t show any significant difference either after removing covariates 
(X2=3.331; df=3; p=.343).   
 
Figure 20 PTI Question 5 - Perceived helpfulness in managing patient’s symptoms by doctor 
In PTI Question 7 – “Would you recommend the PD_Manager system/Diary to other people with Parkinson’s?”, 
again, no effect for covariates were found. The model including just the main factors resulted instead 
significantly fitting the data, showing a difference for the answer “Yes” (B=20.079; W=728.29; df=1; p<.001) to 
be more likely associated to PD_manager group. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PD manager
Diary
How helpful is information to you for managing symptoms
Very helpful
Quite helpful
Neither helpful
Not helpful
Not helpful at all
0% 20% 40% 60% 80% 100%
PD manager
Diary
How did information affect your discussion with doctor
A lot easier
Slightly easier
No differences
A lot more difficult
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Figure 21 PTI Question 7 - Patient’s recommendation 
In PTI Question 8 – “Would you use the PD_Manager system again in the future if your doctor suggested it?”, no 
influence for covariates were found. The test was re-run including just the main factors which resulted instead in 
a model significantly fitting the data, which showed a difference for the answer “Yes” (B=20.186; W=490.73; 
df=1; p<.001) to be more likely associated to PD_manager group. 
 
Figure 22  PTI Question 8 - patient’s desire to use again the monitoring system 
The regression model for PTI Question 9 – “Would you have preferred to have completed a daily 
diary/PD_manager over the last 2 weeks than having the PD_Manager system” – turned out to not fitting the 
parameters used as covariates. However, after the re-run of the analysis, excluding the non-influencing 
covariates, the answers “Diary” and “Maybe, I don’t know” resulted significantly different for the PD_manager 
group and inversely related to the Control Group (B= -3.93 W=13.36; df=1; p<.001) and (B= -2.78 W=15.58; df=1; 
p<.001). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PD manager
Diary
Would you recommend to others?
Yes
Maybe
No
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PD manager
Diary
Would you use again?
Yes
Maybe
No
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Figure 23 PTI Question 9 - Preference on monitoring system, regardless the system tried 
The regression model for PTI Question 10 – “How do you think the symptom diary would compare to the 
PD_Manager system in helping your doctor to understand your problems and plan your treatment?” – turned 
out to be fitting the data, by removing the non-influencing covariates. The answers “PD_manager more helpful” 
resulted significantly different for the PD_manager group (B= 2.22; W=4.38; df=1; p=.04) and (B= -2.78 W=15.58; 
df=1; p<.001). 
 
Figure 24 PTI Question 10 - Comparison between Monitoring systems in perceived helpfulness for doctors 
  
0% 20% 40% 60% 80% 100%
PD manager
Diary
Would you have preferred the …
Diary
Maybe, don't know
PD_manager
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PD manager
Diary
How do you think diary compares to PD_Manager to help doctor plan your 
treatment?
Both would be helpful
Diary more helpful
PD_manager more helpful
Neither helpful
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The ratings observed from patients have been related also to the ratings provided by the Caregivers, showing 
that a significant degree of agreement was present for all the answer going from PTIQ1 to PTIQ5, and PTIQ8 and 
PTIQ10 for both groups. A different pattern, of non-significant agreement was found for the answers to PTIQ7 
and PTIQ9 for the PD_manager group and for PTIQ9 for the Control Group (symptoms diary). The correlation 
matrix and respective value of Spearman R and significance are displayed in tables 13 and 14. 
Group Item PTIQ1-CG PTIQ2-CG PTIQ3-CG PTIQ4-CG PTIQ5-CG 
PD_manager 
PTIQ1 .782** .012 .166 -.039 .047 
PTIQ2 -.132 .900** -.103 .089 -.119 
PTIQ3 .066 .111 .661** .447** .552** 
PTIQ4 -.054 .137 .524** .774** .262 
PTIQ5 .154 -.152 .603** .287* .813** 
Diary 
PTIQ1 .898** .574** .167 .436** .045 
PTIQ2 .674** .917** -.121 .387* -.048 
PTIQ3 .074 -.049 .669** .000 .176 
PTIQ4 .438** .457** -.006 .760** -.105 
PTIQ5 -.057 -.085 .302 -.092 .647** 
Table 13 . Correlation between patients and caregivers answer to PTI. * Correlation is significant at the 0.05 level (2-tailed). ** Correlation 
is significant at the 0.01 level (2-tailed). 
 
 
Group Item PTIQ7-CG PTIQ8-CG PTIQ9-CG PTIQ10-CG 
PD_manager 
PTIQ7 .253 -.067 -.031 .096 
PTIQ8 .053 .563** .125 .111 
PTIQ9 .044 -.298 .248 .061 
PTIQ10 .193 .009 -.114 .277 
Diary 
PTIQ7 .860** .540** -.030 .106 
PTIQ8 .477** .858** .131 .223 
PTIQ9 -.244 .015 .188 -.064 
PTIQ10 .236 .243 .084 .676** 
Table 14 . Correlation between patients and caregivers answer to PTI. * Correlation is significant at the 0.05 level (2-tailed). ** Correlation 
is significant at the 0.01 level (2-tailed). 
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Correlation with Technology Acceptance Measure 
The relationship between the expectations before starting the trial – measured with the Technology Acceptance 
Measure – and the answer and opinion about the PD_manager/Diary were also explored. The correlation of 
TAM score with PTI answer showed just two significant associations between the level of positive expectations 
and the answer to PTIQ3 and PTIQ4 both insisting on the usefulness information area. No associations were 
found for the Diary Group (Table 13). 
PD_manager Group  Symptoms Diary Group 
PTI TAM 
 
PTI TAM 
PTIQ1 .029 
 
PTIQ1 .019 
PTIQ2 .219 
 
PTIQ2 -.169 
PTIQ3 .321* 
 
PTIQ3 .061 
PTIQ4 .376** 
 
PTIQ4 .032 
PTIQ5 .182 
 
PTIQ5 .079 
PTIQ6-1A -.094 
 
PTIQ6-1A . 
PTIQ6-1B -.093 
 
PTIQ6-1B . 
PTIQ6-1C .063 
 
PTIQ6-1C . 
PTIQ6-1D .009 
 
PTIQ6-1D . 
PTIQ6-2A .010 
 
PTIQ6-2A . 
PTIQ6-2B .233 
 
PTIQ6-2B . 
PTIQ6-2C .147 
 
PTIQ6-2C . 
PTIQ6-2D .019 
 
PTIQ6-2D . 
PTIQ6-3A .037 
 
PTIQ6-3A . 
PTIQ6-3B -.081 
 
PTIQ6-3B . 
PTIQ6-3C .117 
 
PTIQ6-3C . 
PTIQ6-3D -.015 
 
PTIQ6-3D . 
PTIQ6-4A .042 
 
PTIQ6-4A . 
PTIQ6-4B .089 
 
PTIQ6-4B . 
PTIQ6-4C -.061 
 
PTIQ6-4C . 
PTIQ6-4D -.129 
 
PTIQ6-4D . 
PTIQ6-CNT-1A . 
 
PTIQ6-CNT-1A -.097 
PTIQ6-CNT-1B . 
 
PTIQ6-CNT-1B .076 
PTIQ6-CNT-1C . 
 
PTIQ6-CNT-1C .099 
PTIQ6-CNT-1D . 
 
PTIQ6-CNT-1D .007 
PTIQ6-CNT-2A . 
 
PTIQ6-CNT-2A -.033 
PTIQ6-CNT-2B . 
 
PTIQ6-CNT-2B -.067 
PTIQ6-CNT-2C . 
 
PTIQ6-CNT-2C -.004 
PTIQ6-CNT-2D . 
 
PTIQ6-CNT-2D -.074 
PTIQ7 .122 
 
PTIQ7 -.002 
PTIQ8 .170 
 
PTIQ8 .141 
PTIQ9 .049 
 
PTIQ9 -.160 
PTIQ10 .058 
 
PTIQ10 -.242 
Table 15 Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed); “.” Cannot be 
computed because at least one of the variables is constant. 
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PD_manager Subcomponent Evaluation 
This sub-section analyses the opinion expressed from participant about the single subcomponents (Insoles, 
Smartband, Smartphone) within the PD_manager Group. The sub components have been assessed in terms of 
Ease of Use, Comfort and Usefulness of information. The ordinal values collected per each area in means of (1, 
“Very”), (2, “Quite”) (3, “Not”), have been analyzed using the Friedman test for non-parametric related-sample 
comparison.  
- Ease of use: the ease of use analysis of subcomponent revealed a significant difference between the 
three different devices PTIQ6-1A(Insoles), PTIQ6-2A and PTIQ6-3A (Smartphone) (X2=7.524; df=2; 
p=.023). The lower mean rank – closer to value 1 (“Very) - was associated with the Smartband (M= 
1.87), whether Smartphone (M=2.19) and Insoles (M=1.94). 
- Comfort: Comfort analysis didn’t show any significant difference between devices (X2 =2.191; df=2; 
p=.334), with mean ranks which display around 2 (Quite). 
- Usefulness for self-management: usefulness for self-management didn’t show any significant difference 
between the devices (X2=2.00; df=2; p=.368), with mean ranks which display around 2 (Quite). 
- Usefulness for doctor: usefulness for self-management between subcomponent didn’t show any 
significant difference (X2=2.60; df=2; p=.273), with mean ranks which display around 2 (Quite). 
Symptoms Diary Subcomponent Evaluation 
This sub-section analyses the opinion expressed from participant about the single subcomponents (Motor 
Symptoms Diary, Non-Motor Symptoms Diary) within the Symptoms Diary Group. The sub components have 
been assessed in terms of Ease of Use, Comfort and Usefulness of information for self-management and for 
doctor. The ordinal values collected per each area in means of (1,“Very”), (2, “Quite”) (3, “Not”), have been 
analyzed using the Friedman test for non-parametric.  
No significant differences in terms of Ease of Use, Comfort and Usefulness of information for self-management 
and for doctor have been found between the two different diaries used by the control group. 
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Compliance, Data Usage And Statistics 
A descriptive and quantitative analysis of compliance and usage have been performed for each patient in 
PD_manager group. Here reported just two examples of two different patients, one with good compliance, one 
with poor compliance. 
 
Figure 25 Patient SC033 Usage from a) wristband and b) accelerometer recordings 
 Patient SC033 used the band as well as the smartphone and the insoles for the whole 2 weeks period. This 
Patient is a 75 years old female, who was diagnosed 20 years ago. She has primary education. Her self-rated 
health status was mediocre (EQ is 14). This health status is reflected in the clinical scales: NMSS score is 45, 
which indicates severe problems, mostly related to seep/fatigue, mood/cognition and gastrointestinal problems. 
The patient described himself as Highly Technophobic. The caregiver was the patient’s 51 years old son who has 
Bachelor education. He feels he has high burden due to PD (Zarit was 24) and described himself as Not 
Technophobic. The caregiver didn’t have a positive attitude towards the PD_manager. These attitudes and the 
fact that the patient described herself as highly technophobic didn’t affect the usage rates which were high. 
Conclusion: disease duration itself seem to not affect the compliance in an old female patient with severe clinical 
status, and the attitudes towards technology may not be primary issues to take into account. 
a) b) 
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Figure 26 Patient SL045 usage from a) wristband and b) accelerometers recordings 
 Patient SL045 used the band for 2 days during the first week he got them and for 4 more days the second week. 
He was carrying the smartphone and wearing the insoles for the whole 2 weeks’ period. Patient SL045 is a 63 
years old patient, which was diagnosed 6 years ago. He has secondary education. His perceived quality of life 
was below average (PDQ8: 46.9%) and his self-rated health status was good (EQ is 10). This health status is 
reflected in the clinical scales: NMSS score is 45, which indicates moderate problems, mostly related to salivation 
and olfactory system problems, and the UPDRS total is 28 which is low for a H&Y stage 3 patient. The patient 
described himself as Not Technophobic. The caregiver was the patient’s 58 years old partner who has primary 
education. He feels she has very little burden due to PD (Zarit was 5) and described himself as Not 
Technophobic. Both the patient and the caregiver thought it would be easy to use PD_manager, they were very 
enthusiastic about its perceived usefulness and they behaviourally intended to support its use, but they were 
not being intrinsically motivated to use it. These attitudes and the fact that both described themselves as Not 
technophobic are in controversy with the relatively low usage rates. Conclusion: a younger patient (63 yo) with 
mild problems who seems to think that the system is useful and easy to use has ca very supporting younger 
caregiver (58 yo) is also very keen to support that use may end up using the band for fewer days the 
PD_manager system than one would suppose. In this case a mildly depressed mood and pain (as reported by the 
patient in EQ and PDQ8) could be the reasons for low usage. Of course, also Bluetooth connection issues 
between Wristband and Smartphone could have affected the amount of recording hours from Wristband. 
More than 3.500 hours of data were recorded in total. The total hours recorded per patient are presented in Fig. 
27. The histogram of recording usage is presented in Fig. 26. Only two patients didn’t use the system at all, while 
a) b) 
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10 were very compliant and used it for more than 100 hours over the 14 days. Overall for all the patients we had 
more than 30 hours of recorded data we were able to extract clinically meaningful information and consistent 
with the baseline UPDRS evaluation. 
 
Figure 28 Total hours recorded per patient 
The total hours of recording were dichotomized in two equally sampled groups (low usage and high usage) in 
order to compare the distribution of each variable against the usage of PD_manager. For numeric variables the 
Spearman correlation against the original (not dichotomized) usage variable was used. For numeric variables we 
also used a t-test in case the variable was normally distributed comparing its value for low and high usage 
groups. If the variable was not normally distributed, then the Wilcoxon signed-rank test was used. For ordinal 
variables the Spearman correlation was used. For mobile phone usage we extracted two measures. The first one 
was the actual data recorded in the 2 weeks of trial, the second measure was the percentage of one-minute 
recordings with motion to the total number of minutes recorded. Minutes with motion are considered those 
having at least one sample with gyroscope energy larger than 2. Based on the results showed in Table 11, the 
UPDRS sub-total scores are the only variables that have some statistical significance for PD_manager usage. In 
fact, usage result to be higher for patients with higher UPDRS, (UPDRS II 7.28 vs 12.92). This trend was also 
observed also in the per patient analysis from which a clear profile of compliant patients could not be extracted. 
  
Figure 27 Number of patients grouped for hours of recordings 
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Variable  Low Usage Group  High Usage group  T-test/Wilcoxon  Spear  
 
Mean Std Mean Std P-value  
Disease duration  7,65 3,20 8,88 4,50 0,26 0,36 
Caregiver Education  10,85 6,36 12,71 4,83 0,26 0,20 
Caregiver Technophobia  2,35 1,38 2,67 1,61  0,27 
Patient age  69,63 11,88 70,31 9,62 0,50 0,69 
Patient Gender (M=1.F=2)  1,44 0,51 1,35 0,49  0,47 
Patient Education  11,00 3,62 11,08 4,78 0,87 0,74 
Patient Technophobia  2,30 1,35 2,58 1,47  0,38 
EQ_5D_5L_1  1,92 0,80 2,19 1,06  0,39 
EQ_5D_5L_2  1,65 0,85 1,65 1,13  0,73 
EQ_5D_5L_3  1,58 0,70 1,65 1,02  0,91 
EQ_5D_5L_4  2,50 0,86 2,12 1,18  0,24 
EQ_5D_5L_5  2,15 0,92 1,88 1,11  0,39 
EQ_5D_5L_Total  9,81 2,81 9,50 4,47 0,77 0,34 
NMSS_Total  39,60 20,43 49,23 49,92 0,74 0,75 
PDQ8_1  1,71 1,08 1,60 1,15  0,80 
PDQ8_2  1,46 0,88 1,96 1,40  0,23 
PDQ8_3  1,96 1,27 1,92 1,50  0,82 
PDQ8_4  1,25 1,07 1,36 1,08  0,67 
PDQ8_5  1,38 0,97 1,40 1,19  0,88 
PDQ8_6  1,17 0,70 1,40 1,04  0,49 
PDQ8_7  2,75 1,33 2,16 1,43  0,15 
PDQ8_8  1,58 0,97 1,96 1,31  0,24 
PDQ8 Total  41,41 17,34 43,00 21,60 0,78 0,71 
Zarit_2  0,91 1,00 1,27 1,28  0,40 
Zarit_11  1,26 1,21 1,05 0,95  0,57 
Zarit_total  8,57 6,67 9,41 5,24 0,64 0,30 
udprsHY  2,71 0,62 2,90 0,48 0,62 0,83 
UPDRS_I_Total  10,36 3,44 11,12 6,39 0,75 0,69 
UPDRS_II_Total  7,28 4,62 12,92 8,33 0,01 0,04 
UPDRS_III_Total  23,27 10,15 31,52 18,25 0,05 0,24 
UPDRS_IV_Total  5,36 3,29 5,52 4,41 0,88 0,76 
UPDRS_Total  46,72 16,13 61,08 31,81 0,05 0,39 
Table 16 comparison of main Clinical scores between low and high usage groups 
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Based on this observation a further analysis was performed on the population with low UPDRS score, in 
particular UPDRS Part II score equal to 15 or less. 
Variable  Low Usage Group  High Usage group  T-test/Wilcoxon  Spear  
 
Mean  Std.  Mean  Std.  P-value   
Disease duration  7,55  3,42  7,28  2,24  0,78 0,78  
Caregiver Education  11,86  5,97  13,28  4,39  0,48 0,22  
Caregiver Technophobia  2,50  1,37  2,72  1,41   0,53  
Patient age  67,50  7,42  67,17  9,25  0,90 0,77  
Patient Gender (M=1.F=2)  1,41  0,50  1,39  0,50   0,90  
Patient Education  11,09  3,69  12,50  3,97  0,29 0,61  
Patient Technophobia  2,36  1,33  2,56  1,62  1,00 0,47  
EQ_5D_5L_1  1,86  0,71  1,67  0,77   0,36  
EQ_5D_5L_2  1,55  0,74  1,33  0,59   0,36  
EQ_5D_5L_3  1,55  0,74  1,39  0,70   0,62  
EQ_5D_5L_4  2,55  0,91  2,00  0,91   0,06  
EQ_5D_5L_5  2,18  0,96  1,72  0,89   0,16  
EQ_5D_5L_Total  9,68  2,63  8,11  2,87  0,07 0,03  
NMSS_Total  39,68  20,11  36,33  29,44  0,24 0,22  
PDQ8_1  1,64  1,09  1,50  0,99   0,90  
PDQ8_2  1,45  0,91  1,39  0,85   1,00  
PDQ8_3  1,95  1,33  1,67  1,28   0,41  
PDQ8_4  1,18  1,10  1,33  1,08   0,52  
PDQ8_5  1,36  1,00  1,17  0,92   0,56  
PDQ8_6  1,14  0,71  0,94  0,73   0,46  
PDQ8_7  2,82  1,37  1,94  1,11   0,02  
PDQ8_8  1,50  0,96  1,67  1,24   0,63  
PDQ8 Total  40,77  17,85  36,28  16,78  0,42 0,29  
Zarit_2  0,95  1,02  0,72  0,96   0,46  
Zarit_11  1,24  1,26  1,11  0,96   0,84  
Zarit_total  8,71  6,91  7,56  4,42  0,54 0,69  
udprsHY  2,75  0,55  2,78  0,39  0,75 0,28  
UPDRS_I_Total  10,36  3,62  9,56  4,68  0,54 0,17  
UPDRS_II_Total  6,55  3,47  7,61  3,27  0,24 0,59  
UPDRS_III_Total  22,14  9,24  21,67  8,55  0,87 0,56  
UPDRS_IV_Total  5,55  3,42  4,22  3,14  0,21 0,46  
UPDRS_Total  44,59  14,75  43,06  14,03  0,74 0,46  
Table 17 Comparison between low usage and high usage in patients with low UPDRS part II score 
3 variables are statistically important and seem to affect the usage of the system: 
- PDQ8 Item 7: Had painful muscle cramps or spasms? (Likert: 1-never to 5-always) 
- The total EQ-5D score which provides the patient’s overall self-rated health status 
- EQ-5D Item 4: PAIN / DISCOMFORT (Likert: 1-“I have no pain or discomfort” to 5-“I have extreme pain or 
discomfort”). 
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Clinicians Study 
Another important task of the project was the creation of Clinician App. This Android based application has been 
conceived to output clear and understandable reports of the patient’s symptoms during the 2 weeks of trial. All 
functionalities of the app are designed to be smart, intuitive and to facilitate the clinician’s analysis of the data 
coming from the recordings. Moreover, the Clinician App is integrated with the DSS System and is able to 
recognize specific patterns of symptoms that could be troublesome for each patient and report an alert to the 
clinician. The App provides  the  necessary  data  visualization  functionalities  required by clinicians, including: 
assessment  (summary  reports  and  charts); clinical  information  (patient’s  History); Motor Symptoms 
(summary  reports  and  charts); tests  (scores of clinical scales  and  questionnaires); a calendar(for  retrieving  
data  for  the  patients); Medication  (past  and  current  plans). The  main  functionality  is  the  presentation  of  
symptom  charts  allowing  the  clinician  to  explore  the  patient  symptoms  and  assess  his  motor  status.  
There  are  five  main  types  of  symptoms  charts: 1) Symptom  Trend  Chart:  the  symptom  trend  chart  
provides  an  overview  of  a  symptom for  a  period  of  time  aggregated  per  day.  This  chart  allows clinicians  
to  monitor  the  trend  of  the  symptom  and  whether  there  are  any  significant  changes  related  to  patient  
status,  change of  habits  or  medication. 2) Symptom  Daily  Pattern  Chart: the  symptom  daily  pattern  chart  
present  symptoms  aggregated  per  time  of  day.  Moreover,  medications  are  overlaid  and  the  tool  gives  
the  user  the  ability  to  compare  daily  patterns  between  different  periods  of  time.    The  specific  chart  is  
probably  the  most  useful  tool  for  the  clinician  for  treatment  planning  since  using  those  charts  can  easily  
check  the  occurrence  of  symptoms  related  to  medication  times  and  decide  whether  some  change  is  
required. 3) Symptom  Day  Chart: clinicians  can use  the  calendar  to  navigate  to  specific  days  and  view  the  
symptoms  as  well  as  medication  intakes  for  the  specific  day. 4) Symptom  Summary: the  symptom  
summary  presents  the  most  important  information  of  symptoms. 5) Patient  Chart: the  patient  chart  
displays  the  patient’s  clinical  information  including  allergies,  demographic data,  other clinical problems, etc. 
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Figure 29 Screenshot from Clinician App:  calendar of recordings. In orange, days with data available. Red 
bars: alerts for time spent with dyskinesia > 50% of the day 
Figure 31 Clinician App's Main Manu Figure 30 DSS suggestion and evaluation of main 
symptoms 
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From this point of view, the clinician’s feedback is crucial to establish if the information coming from the System 
could influence clinical decisions. Feedback was sought by means of a structured interview schedule on 
perceived usefulness to professionals: the clinicians were asked to comment on how easy it was to interpret the 
data generated by the devices and the symptom diary, to use this data in changing the treatment and care 
Figure 33 Example of Symptom Trend Chart for bradykinesia. The Bradykinesia estimated UPDRS subitem score is depicted for each 
day of the recordings. Patient SC_28 seems to have medium bradykinesia, quite stable during the 2 weeks 
Figure 32Symptoms Daily Pattern Chart for Tremor: the graph shows the 2 weeks mean time spent with tremor, for each hour of 
the day. The black bars represent the Levodopa doses. Patient SC_28 has tremor, but it is responsive to Levodopa administration 
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management of participants. A total of 12 Clinicians were recruited and provided feedback data. Table 18 shows 
the characteristics of the clinicians who responded. Most had been practicing as neurologist for at least 5 years 
and dealt with significant numbers of people with Parkinson’s on a monthly basis. Most also were familiar with 
smart phone use. The average score for PD_manager on the System Usability Scale was to the 72.5 which is 
above the widely accepted threshold of 68. The range was 12.5 to 100. For the other various components of SUS 
questions, more than 75% of the Clinicians have consistently highly rated the PD Manager system, but as 
depicted in the graphs below, 2 or 3 clinicians were consistently not satisfied or did not find the system helpful.  
 
Table 18 Clinicians’ characteristics 
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Figure 34 graphs showing clinicians’ perspective on Clinician App 
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DISCUSSION 
 
In this PhD project, a novel mHealth platform for Parkinson’s disease management has been designed, 
implemented and tested on patients and caregivers. The first phase of the project was focused on devices 
selection and on the development of algorithms that could be able to recognize and detect the main motor 
symptoms of the disease, based on the raw data gathered from the selected devices. To do that, a Pilot Study 
have been designed and the devices have been tested on 20 patients in controlled environment (hospital or 
ambulatory room). Several recordings have been performed for each patient (both in On and Off condition) and 
all the tests have been video recorded. The patients’ performances have been evaluated and scored using 
validated clinical scales during the recording sessions and also by analysing video recordings. In parallel, 
technical partners have studied the raw motor data coming from the devices and have found the right 
algorithms to detect and quantify tremor, dyskinesia, bradykinesia, gait impairment and FOG episodes. By 
comparing the results coming from the symptoms quantification and detection to the clinical scores given by 
doctors, we found a high accuracy in symptom recognition. For example, the gait algorithm is able to 
discriminate patients without gait impairment from patient with gait impairment with an accuracy of 91% and 
also regarding FOG detection, 90% of the measurements have been correctly detected as either having FOG or 
no FOG. The false-positive rate was 6%, the false-negative rate 4%. Analyzing tremor algorithm, we found a high 
correlation between estimated Tremor UPDRS amplitude and constancy, compared to those scored by clinicians. 
Dyskinesia detection accuracy varies from 88% with a 5 minutes time window a 98% for a 30 minutes window. 
The dyskinesia classification between slight/mild and moderate/severe had an accuracy of 92%. During the Pilot 
study, also the cognitive App has been developed and tested, with the achieved goal of gathering useful 
feedback by patients regarding possible improvements of test/games functionality and app usability. Also, for 
the Voice Recognition App a sufficient amount of audio recordings has been gathered, in order to feed algorithm 
that is now able to analyze patient’s voice and evaluate the degree of vocal impairment in terms of UPDRS 
subitem 3.1 estimation, with a good sensitivity for Off and On conditions. This is the first step for a more 
ambitious goal, that aims to perform a “Sentiment analysis” by recognizing selected words and parameters 
during patients’ free speech. In this way it will be possible, for example to estimate the degree of depression or 
anxiety.  
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Given these promising results, a Multicentric Study has been planned to test PD_manager system at patient’s 
home and assess its acceptability and usability, compared to current gold standards for motor symptom home-
based monitoring. We have recruited a total of 136 couples of patients and carers, that, given the clinical 
characteristic reported, represents a good sample of moderate-advanced PD. It was crucial to test PD_manager 
on patients with moderate-advanced disease because is exactly in this stage that a monitoring system could give 
the maximum benefit in terms of standard care improvement.  As depicted in the graph PTIQ1 (Fig. 16), patients 
in PD_manager group tend to consider the system quite easy to use, while some patients in diary group consider 
the diaries quite difficult or very difficult to use. This suggests that the system has been accepted and quite well 
tolerated during the intervention period of two weeks in their everyday life. The ease of use is also reflected by 
the low rate of drop-out occurred in the study and by the high compliance in wearing the devices proposed. 
PTIQ2 (Fig. 17) shows how in both groups the majority of patients interact with the monitoring for less than 30 
minutes every day. This is much evident when considering only diaries group, in fact there is a relevant quote of 
patients in PD_manager group that spend more than 30 minutes or even more than 2 hours per day using the 
monitoring system. This suggest that patients were positively involved in using the system, reflecting a higher 
compliance if compared to diaries which were, quite often, hard to fill on time and with a good accuracy. PTIQ3 
(Fig. 18) and PTIQ4 (Fig.19) indicated how for both groups a monitoring system could be quite helpful for self-
management of the disease. The analysis did not show any difference between PD_manager system and 
Symptoms Diary about giving useful information to patients for their self-management. Both systems were 
evaluated as useful, however we must consider that patients were asked to fill a diary, and most of them do not 
use such technique in the everyday life. The majority of diaries filled contained different gaps and the bias 
related to the self-assessment should be always taken into account. On the other side PD_manager might not 
have shown a difference because patients were not allowed to see their own data during the Study. However, 
there was a good consideration regarding the usefulness of monitoring techniques. This shows how important 
could be a monitoring system for PD patients, no matter if based on diaries or on automated mHealth system, in 
order to give information on their clinical status. In PTIQ5 (Fig. 20) is depicted the distribution of patients based 
on the perceived level of usefulness for interaction with doctors. There are not clear differences between the 
two groups, but for both the majority find that the systems could be very or at least slightly useful in facilitating 
their interaction with doctors. The PTIQ7 (Fig.21) analysis observed how almost all patients would suggest a 
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monitoring system (diaries or PD_manager) to another patient. However, the significant association between 
the high recommended value of the system used and the PD_manager group, might indicate how patients trust 
and promote new innovative and automatic systems for monitoring the clinical status of Parkinson’s disease. 
PTIQ8 (Fig. 22) results showed how people who have tried the PD_manager system, trust the innovative 
technique for monitoring their symptoms. They’re more likely to use a similar system if it would be present on 
the market and if the doctor would advise them about using it. PTIQ9 (Fig.23) graph shows the distribution of 
the desired system to try before the randomization. There is a homogeneous distribution between patients from 
diary group, while the majority of patients in PD_manager group desired to try PD_manager system. PTIQ10 
graph (fig. 24) shows the results of a judgement on which of the two systems would be more helpful, no matter 
which one the patient has tested. Interestingly also the majority of patients that tried diaries said that 
PD_manager would be better, while only a few patients from PD_manager group said that diaries would be 
better. The degree of agreement was found to be high for all the opinion emerging about the ease of use and 
the usefulness of information related to the two systems proposed. Although Caregivers tend to have a less 
degree of agreement about the willingness of using PD_manager in the future. On the other hand, interestingly 
for the Symptoms Diary Group, Caregivers show a low degree of accordance with patients about re-using the 
same system, showing as much more oriented in trying also an innovative mHealth system. Concerning the 
attitudes toward technology and the positive expectation toward PD_manager system resulted in a major 
influence in giving more positive ratings regarding the usefulness of information, whether no other relationships 
where found to be influencing the rest of opinions. Finally, the analysis of subcomponent showed how the ease 
of use was less accentuated for the smartphone and the sensor insoles, while the wristband resulted to be more 
appreciated. These results are in line with the usage and compliance data and indicate how different kind of 
technology should be differently address in order to obtain a good user experience. The wristband resulted to be 
a wearable device for meeting the requirement of quality movement data gathering and good acceptance and 
wearability. The smartphone werability – used in the study both as gateway and application - might be improved 
in terms of clarity and intuitive interaction and access to the different functionalities of the app (e.g. user 
interface designed for reducing the impact of motor deficits). The sensor insoles might not be easy to use in the 
everyday life context for prolonged period of time, however the high technical performance in detecting walking 
abnormalities and freezing of gait, showed during the validation study, makes the sensor insoles a more 
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appropriate and useful device for a short-time assessment. Motor symptoms diary and non-motor symptoms 
diary didn’t show difference in ratings in any of the area explored. Patients have positively evaluated such kind 
of technique for self-monitoring, however despite the consistency of the answer, both diaries showed gaps and 
missing data, which do not overlap with the opinion given at the end of the trial. We might say that completing a 
daily diary it’s easy to use, it’s useful in providing information to the doctor, whilst perpetrating such task for 
longer period of time could affect the quality and reliability of data collected. From the usage analysis, we found 
a higher adherence in patients with higher UPDRS scores, in particular in those with high UPDRS II score, that 
evaluates daily living impairment. This is reasonable, since they are eager to provide more data to their clinicians 
and receive better management of their symptoms. This is even more clear when considering only patients that 
have motor problems with an impact on daily life activities. One of the most interesting finding is that 2 out of 3 
items are consistent and are directly linked to the feeling of pain and/or discomfort which was observed in 
patients with low usage of the devices (even among patients with lower total UPDRS). Pain is a common, but 
perhaps unexpected, non-motor symptom of PD. At least 55% of PD patients can experience some form of 
discomfort during the course of their disease. Usually, pain is more frequent in women and in subjects with 
medical conditions that predispose to painful symptoms. However, some types of pain are related to Parkinson's 
motor or non-motor symptoms, for example sleep/fatigue disturbances or mood/cognition disorders. Pain, like 
most PD symptoms, can fluctuate, in fact an amount of PD patients reports a positive pain response to 
assumption of dopaminergic medications. This kind of patients are usually more affected by dystonic pain, 
characterized by cramps and muscular pain, that is generally worse during Off periods. It is possible that in 
patients with low motor disability, pain represents an obstacle for the compliance of wearable devices usage. 
The other finding is that worse perceived patient’s self-rated health status the day of study inclusion which of 
course is influenced by pain, can be related to lower usage of PD_manager and similar systems. The motor data 
gathered during the Multicentric study underwent to further evaluation by the engineers, to test the efficacy of 
the algorithms developed during the Pilot study. The result is that PD_manager can be used to accurately 
discriminate patients with mild to severe Tremor (UPDRS subitem 3.18 >1) and Dyskinesia (UPDRS subitem 4.1 
>1) versus patients with no or slight tremor and dyskinesia (Area under the curve is 97% and 92% respectively). 
The number of patients with UPDRS subitem 4.1 >1 (mild to severe dyskinesia) was limited. Finger tapping test 
results are also significant and correlated with UPDRS subitem 3.4. The correlations between the PD_manager 
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system and the patient-reported scores for freezing and gait are medium (about 0.4) but comparable to the 
doctor-rated scores and the patient-reported scores correlations (approximately 0.5). To sum up PD_manager 
modules can be used in for PD symptom home-monitoring for making informed decisions and providing better 
and personalized treatment. However, the efficacy of PD_manager in terms of modification of drug treatment or 
changes in other therapeutic choices cannot be assessed the moment, since the platform has not yet the C.E. 
approval for medical device. Any intervention that can influence patient’s safety can’t be applied if based on 
information obtained by devices or software that had not yet received this approval, so this will be one of the 
next steps of the PD_manager development. 
PD_manager system has several possible exploitations. The main application could be in clinical routine, allowing 
clinicians to obtain objective data about motor and non-motor features, and therefore giving an help in taking 
therapeutic decisions, also with possible reduction of time spent per single patient in ambulatory room. A 
possible scenario could be represented by a 2 steps visit, where in the first the clinician modify the drugs plan 
and then gives PD_manager to patient. The patient uses the System at home for a limited period of time (e.g. 2 
weeks) and in the meantime his/her data are sent in cloud and stored on a safe server, where the clinician can 
access. In this way the clinician can assess in real time the efficacy of the pharmacologic modifications and 
eventually change the therapeutic suggestions during the second visit, when de patient came back to return the 
devices. During PD_manager Project, a DSS system has also been developed. The DSS can put a “red flag” on 
symptoms that appear to be particularly severe or troublesome for patient and that must be more accurately 
evaluated by clinician. The DSS has been developed based on the therapeutic decisions of expert clinicians. The 
classification accuracy, measured on the PPMI data, was generally quite low There are many possible 
reasons for that, from a high variability and inconsistency of decisions captured in the PPMI, to the 
fundamental difference between normative knowledge, which is captured in DEX models, and descriptive, 
real-life performance, which is reflected in the PPMI. For the PD_manager DSS, which is aimed at 
identifying situations that require medical response rather than giving instructions of how to react, the 
normative aspect seems more relevant. When measured in comparison with physicians on selected use 
cases, the performance of the models turned out to be much better. Obviously, PD_manager, like any other 
medical monitoring system, can’t be used as a surrogate of medical examination or patient’s interview. From 
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patient’s perspective, PD_manager can be used as a useful tool for self-monitoring and self-care, for example 
watching at the educational video gallery or annotating the most disabling symptoms. The system can be 
implemented also with a pill administration reminder, that helps patient and caregiver on maximizing the 
adherence to pharmacological therapy suggested. Unfortunately, at this level of development, the pill reminder 
is considered an intervention that can influence patient’s safety, so for the reasons explained above, this 
functionality has not yet been tested. However also some critical issues emerged from the multicentric study. 
For example, all involved actors need some time to be trained before using the system for the first time. This 
time has been estimated in at least one hour, in particular when considering patients with limited familiarity to 
smartphone technology, in fact we observed that some patients were not able to use the smartphone while they 
had no problem wearing the band and the insoles. The system should be plug and play and independent from 
charging for as long as possible, at the moment the duration of home recordings is limited mainly by the data 
storage in insoles’ built-in memory. Technical support should be provided at least at the beginning of any large-
scale deployment. In a possible scenario of a clinical use of PD_manager, delivery and return of the devices 
should be organized also through a courier agency, especially for patients living in remote areas. Also, the fact 
that many patients tend to not wear closed shoes during summer season must be taken into account for a 
correct insoles’ usage. A possible pitfall of the System could be represented by cognitive impairment that 
commonly affects patients in advanced stages of the disease and that could reduce its efficiency in a context of 
real-life usage. The selected exclusion criteria cannot allow to have objective data about this aspect since we 
have purposely decided to not include cognitive impaired patients in this study. However, we can hypothesize 
that also in demented subjects, an automated way to detect motor symptoms could be anyhow more effective 
than self-reported symptoms, since for these patients is even more difficult to correctly report their symptoms 
and they surely cannot properly fill the home diaries. Obviously, in this particular subset of patients, the 
presence of a caregiver will be essential to wear devices and for their management at home. Another issue that 
could affect the reliability of the System is the grade of education. We have observed no differences in terms of 
years of educations when dividing the PD_manager group in high and low usage groups, pointing out that the 
usage is not influenced by education. However, this aspect needs to be taken into account when an analysis of 
efficiency/efficacy of the System will be performed. We also have to consider that this kind of monitoring system 
is designed to be used by patients of future, that probably now are in their 50s or 40s. This population will be 
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much more familiar with technological devices than over 65 years of age patients that have currently tested the 
System. 
A cost analysis has also been performed by health economics partners in University of Surrey (UK). Costs are 
obviously higher for PD_manager group because of technical devices and software used for system set up. In 
particular the main costs are represented by insoles and Moticon software, however they fall if spread on more 
patients, since software costs are fixed and devices can be re-used by many patients. Costs of diaries usage are 
almost negligible. It is expected, however, that with future  refinements  in  the  technology  and  scaling  up  of  
use,  costs  per  patient  will  decline.  In addition, health professionals will become  more  familiar  with  the use  
of  the  technology  and  the  time  that  they  spend  on managing  and  interpreting  the  data  will  decline.  
Modifications to the technology following  feedback  from  early  testing  will  result  in  improvements  in  
features  such  as  comfort  and  ease  of  use,  which  coupled  with  marketing  initiatives  will  result  in  
increased  uptake  and  the  opportunity  to  capitalize  on  economies  of  scale  in  production. An effective 
costs/advantages analysis can be performed only in the context of a study that evaluates the efficacy of the 
systems in terms of optimization of therapies and reduction of consultation time on the basis of data generated 
by PD_manager system 
In clinicians’ study, a good attitude towards Clinician App was observed: the app was found easy to use and 
relevant in terms of information provided for medical management of PD. Only two clinicians were skeptic about 
the usefulness of PD_manager in clinical routine, but we have to consider that someone of them obtained low 
scores at the TAMM scale and 1 of them reported to never use a smartphone in daily life. However, the App was 
tested only on 12 clinicians and larger sample should be obtained to perform a better data analysis. 
In conclusion, this PhD study generated new insights into the use of wearable sensors in daily living by PD 
patients, and given the potential of the data gathered, it will make further contributions with significant impact 
on the integration of self-collected information into clinical practice for PD patients. This project represents the 
first step towards building a reliable system that integrates real-life information into clinical decisions. The next 
step for PD_manager will be an evaluation of effectiveness of medical intervention based on data coming from 
the mHealth platform, compared to effectiveness of traditional management based only on data reported by 
patients and clinical examination.  
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